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Preface 
Vascular surgery is one of the specialties of surgery focusing on the vascular system of 
the body, i.e. arteries and veins. The unique feature of this specialty is, unlike other
surgical specialty, that vascular surgeons routinely perform not only the conventional
open surgery but also the diagnostic and interventional endovascular procedures. For 
that reason, the field of vascular surgery has evolved rapidly since the introduction of
the endovascular aneurysms repair (EVAR) as well as the numerous techniques and 
devices of endovascular procedures for peripheral artery disease and varicose veins.
This book aims to provide a brief overview of conventional open vascular surgery,
endovascular surgery and pre- and post-operative management of vascular patients. 
The collections of contributions from outstanding vascular surgeons and scientists
from around the world present detailed and precious information about the important 
topics of the current vascular surgery practice and research. This book covers a wide
variety of issues and topics of the vascular surgery. I would like to acknowledge the 
authors around the world for their excellent contributions to this book. I also would 
like to express my special thanks to the managing editor of INTECH for providing me
numerous supports and advices.
I hope this book will be used worldwide by young vascular surgeons and medical
students enhancing their knowledge and stimulating the advancement of this field. 
Dai Yamanouchi, MD, PhD
Assistant Professor of Vascular Surgery 
University of Wisconsin School of Medicine and Public Health 
USA
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1. Introduction 
Significant atherosclerotic disease affecting also the carotid artery system is encountered in a 
substantial number of patients undergoing coronary artery bypass grafting (CABG) [1]. The 
optimal surgical management to prevent stroke and cardiac events in this subset of patients 
remains unclear [2-5]. Among patients undergoing carotid endoarterectomy (CEA) 
procedure in the Veterans Affair Cooperative Study and in the Asymptomatic Carotid 
Atherosclerosis Study, respectively 20% and 49% of deaths were related to cardiac causes 
[4]. Similarly, the incidence of perioperative stroke in patients undergoing CABG is high in 
those affected by concomitant significant carotid disease [2-4]. The combined surgical 
approach is associated with an increased risk for mortality and morbidity [5]. In the staged 
surgical approach which addresses the carotid artery lesion with carotid endoarterectomy 
first, followed several days to several weeks by CABG, incidence of perioperative stroke 
during CABG is reduced .However, the risk of myocardial infarction (MI) during the CEA 
procedure and in the period preceding CABG remains high (6%) [6]. Carotid artery stenting 
(CAS) using cerebral protection devices is rapidly evolving as an alternative to carotid 
endoarterectomy [7], mainly for patients with severe carotid artery stenosis at high surgical 
risk [8], such as patients with coronary artery disease. A staged CAS-CABG approach has 
been recently proposed, but the need of a dual anti-platelet aggregation therapy lasting 3-4 
weeks after stenting may represent a limitation for CABG [9]. 
2. Clinical experience 
In our Institution in 2005 we introduced a new therapeutic strategy consisting of a 
simultaneous hybrid revascularization by CAS, immediately followed by CABG and cases 
 The Author(s). License  InTech. This chapter is distributed under the terms of the Creativ  Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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have been colleted in the SHARP study (“Simultaneous hybrid revascularization by carotid 
artery stenting and coronary artery bypass grafting”) (Figure 1). 
 
Figure 1.  
As compared to the combined or staged surgical strategy currently adopted, the new hybrid 
approach CAS-CABG can reduce the incidence of serious perioperative adverse events and 
minimize surgical trauma. Surgical time and surgical trauma are shorter and less extensive 
as compared to combined CEA and CABG. Risk of MI is expected to be reduced, by 
shortening the interval between the two procedures [10, 11].  
Eligible criteria for the enrolment: 1) concomitant critical carotid and coronary disease with 
coronary arteries suitable for CABG; 2) EuroSCORE ≥5; 3) a carotid artery stenosis ≥50% in 
the symptomatic disease or ≥80% in asymptomatic disease, as determined by the North 
American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria [2]. The presence 
of carotid artery stenosis was evidenced by eco duplex scanning, then confirmed by catheter 
angiography and either magnetic resonance angiography or computed tomography (CT) 
scan angiography. A CT scan with or without angiographic dye, depending on 
preprocedural serum levels of creatinine, was performed in all patients to provide the 
maximum information regarding the aortic arch, the extent of aortic disease and the brain. 
In case of bilateral carotid artery stenosis the choice of the carotid artery to treat was made 
according to clinical criteria or to the severity and morphology of plaque in case of 
asymptomatic patients. In a very few instances of bilateral subocclusive carotid stenosis, 
successful bilateral CAS has been performed, immediately followed by CABG. 
CAS procedures were performed under local anaesthesia through a percutaneous transfemoral 
access with the use of stents and protection devices. An introducer sheath was positioned in the 
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femoral artery, and heparin (1 mg /kg) was administered intra-arterially as a bolus. Then a 
guiding catheter was placed in the common carotid artery, proximally to the bifurcation. A 
distal filter protection was used in all patients. At the end of the procedure, patients were 
transferred directly to the operating room; CABG procedure was performed by means of 
normothermic cardiopulmonary bypass in the majority patients; in few cases off-pump CABG 
procedure was performed according with the choice of surgeon and comorbidity of patient. 
2.1. Periprocedural pharmacological protocol 
Aspirin 100 mg daily was started at least 2 days before CAS and daily after combined 
procedure was performed. Heparin was administered 1 mg /Kg as a bolus intra-arterially 
immediately before the stent implantation procedure and in the operating room before the 
cardiopulmonary bypass 2 mg/Kg as a bolus. Activated clotting time was checked every 30 
minutes and was constantly maintained ≥ 250 sec. until the CABG procedure and ≥480 
seconds until the end of the cardiopulmonary bypass. Tranexamic acid 2 g in bolus was 
administered as an antifibrinolytic agent over 20 minutes before sternotomy and then as 
endovenous infusion (0.5 g/h) until the patient was admitted to the postoperative intensive 
care unit in most of cases. Clopidogrel, 300 mg as a loading dose, followed by 75 mg per day 
for 1 month was started in the intensive care unit via a nasogastric tube 6 hours after the end 
of CABG surgery, providing that surgical bleeding from the thoracic drains had either 
stopped, or when it was less than 50 mL/hr for 3 consecutive hours from the sixth 
postoperative hour on (Figure 2). 
 
Figure 2.  
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The primary end points analyzed were the incidence of stroke, MI or death at 30 days after 
CAS-CABG and at a mid-term follow-up. 
2.2. In-hospital and follow-up results 
One-hundred and forty eight consecutive patients between January 2005 and November 2011 
underwent CAS-CABG treatment. Mean age of patients was 68±8 years, means EuroSCORE 
8.6±2.5; 22 patients (14.8%) were affected by symptomatic carotid disease; 67 (45%) had 
bilateral carotid stenosis. Left internal mammary artery was used as graft to the left anterior 
descending artery in all patients, bilateral mammary artery in 20 cases (13.5%). (Table 1).  
 
Variable Value 
Number of patients 148
Age - years * 68 ± 8
Male - n. † (%) 118 (79)
CCS pre-op - mean * 2.7 ± 1
CCS class III/IV ‡ - n. (%) 93 (63)
Instable Angina- n. (%) 34 (23)
NYHA – mean * 2.2 ± 1
Bilateral carotid stenosis- n. (%) 67 (45)
Previous Stroke o TIA - n. (%) 22 (14,8)
Surgical Risk** 8.6 ± 2.5
Doppler velocity of internal carotid artery. -  mean * 325 ± 40 cm/sec 
* ± DS 
† n. = number 
‡ Following classification of Canadian Cardiovascular Society (CCS). 
§ Sierum creatinin concentration >1,5 mg/dl and clearence of creatinin <50 ml/min. 
** Surgical Risk as EuroSCORE I (Eur J Cardiothor Surg 1999; 15:816-823).  
MI= miocardial infarction; LVEF =Left ventrical ejection fraction. 
Table 1. Preoperative details of patients. 
Clinical major outcomes at 48 months are reported in Table 2 
 
Operative mortality 1.3% 
Periprocedural Stroke 1.3% 
Perioperative MI 0 
Re-exploration for bleeding 2.0% 
Stroke, MI or death within 48 months 6.1% 
MI = myocardial infarction 
Table 2. Incidence of Clinical Events up to 48 months 
In the first one hundred patients we report a mean follow-up of 40±25 months, 97% complete. 
In these patients we found at the end of follow-up 9 deaths whit a cumulative survival rate of 
89%; furthermore we observed a very low mortality rate for cardiac late death (97±2%) and an 
high rate of freedom from fatal stroke (we registered just one case of fatal stroke during follow-
up) (98±2%), MI (96±3%), and cerebrovascular events (90±6%). (Figure 3-6) 
Simultaneous Hybrid Revascularization by  




Figure 3. Survival rate at follow-up 
 
Figure 4. Kaplan Meier: Freedom from cardiac late death. 
 
Figure 5. Kaplan Meier: Freedom from miocardial infarction. 
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Figure 6. Kaplan Meier: freedom from fatal stroke. 
Internal carotid artery systolic blood flow during follow-up, showed significant improvement 
as compared to preoperative mean value. (67±10 cm/sec vs. 325±40 cm/sec, P < .001). 
3. Comments 
Neurological complications are relatively common after CABG, especially in high-risk 
patients. Carotid artery disease is significantly associated with a type I adverse neurological 
outcome (i.e., death due to stroke or hypoxic encephalopathy, nonfatal stroke, TIA, stupor, 
or coma at the time of discharge). Significant carotid artery stenoses are associated with up 
to 30% of early postoperative strokes following CABG. Preventing stroke and 
cardiovascular events after CABG is an important and complex issue. Concomitant carotid 
artery disease might be a major factor contributing to the occurrence of postoperative stroke. 
Moreover, carotid artery disease might be a marker of diffuse atherosclerosis, affecting also 
aortic arch, arch vessels, and intracranial vessels. In this high risk population, a simplified 
operative management like hybrid revascularization by CAS and CABG can minimize the 
negative impact of diffuse atherosclerotic disease. In fact, our findings indicate that, in 
patients with combined carotid artery disease and coronary artery disease, the proposed 
hybrid approach is a feasible therapeutic option with good immediate and short-term 
clinical results. The recently reported incidence of perioperative stroke and mortality 
following CEA and CABG is not negligible, ranging between 8.3% to 10.3% [12]. According 
to these results, in a previous series of 100 consecutive patients undergoing combined 
surgical revascularization at our Institution between 1991 and 2002, the 30-day mortality 
and stroke rate was 10% and 1.1%, respectively, with a mortality rate of 14.5% when the 
standard EuroSCORE was ≥ 6, and 3.4% when it was lower than 6. These high-risk patients 
could be treated by an alternative strategy such as the hybrid approach proposed in this 
study. As compared with combined surgical revascularization, the hybrid strategy requires 
a shorter surgical time and less extensive surgical trauma, thus reducing cofactors known to 
increase morbidity and mortality. In particular, in high-risk patients for CEA, mainly due to 
severe CAD, the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High 
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Risk for Endarterectomy) trial showed that CAS was safer than carotid endarterectomy, 
because it had a lower postprocedural risk of myocardial infarction at 30 days as compared 
with surgery. This is likely to be the case mainly in patients with elevated surgical risk, such 
as the patients involved in the SHARP study. In particular, when the standard EuroSCORE 
is 8, as it is in our study, the surgical mortality rate might be greater than 10-12%. In this 
high-risk subset of patients, specific surgical complications are also increased up to 55% [13]. 
When both internal carotid arteries have significant stenosis, the risk of stroke after cardiac 
surgery is particularly high (25%). With the percutaneous hybrid approach, in our study the 
stroke rate was only 1.3%, considering that 45% of our patients had bilateral internal carotid 
artery disease. Potential adjunctive advantage of the simultaneous hybrid approach as 
compared with a combined surgical approach is that during the CAS procedure the patient 
is awake and the neurological outcome will be known instantly rather than after the patient 
emerges from general anaesthesia. Another most important finding of our study was the 
absence of periprocedural rate of MI. By observing the proposed protocol, the risk of MI, 
especially during carotid surgery or in the time elapsing between the two procedures (CEA 
or CAS and CABG after 3-4 weeks from carotid procedure), is virtually eliminated. In the 
two-stage procedure, the rate of MI when the patient is waiting for CABG after carotid 
artery procedure is about 5-6%. Finally our study also demonstrated safety of the 
pharmacological protocol and the timing of antiplatelet administration proposed: the 
bleeding rate after surgical intervention was low.  
The proposed hybrid approach conferred an operative mortality rate comparable to that of 
isolated CABG. 
In conclusions, the new hybrid approach is aiming to reduce risk of myocardial infarction, 
of bleeding after CABG and risk of death and major cerebrovascular complications. Reduced 
mortality and morbidity are expected to reduce also in-hospital stay and costs. Therefore, in 
patients with combined carotid artery and coronary artery disease at higher surgical risk, 
the proposed hybrid approach seems to be a possible, advantageous and safe alternative 
therapeutic strategy.  
At a mid-term period, a high rate of event-free survival and freedom from cerebrovascular 
events can be expected. 
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1. Introduction 
It is well known connection between the stroke and diseases of carotid artery (stenosis, 
aneurysm, kinking). In the XIX century postmortem studies showed association of ischemic 
brain lesions and plaque formation in carotid bifurcation [1]. Later in 1937 Egaz Moniz 
performed first angiography while neurologists started to consider connection between 
carotid and brain lesions, and very soon idea for surgical treatment was born [2]. In 1951, in 
Buenos Aires, Carrea performed external to internal carotid artery bypass, and published it 
in 1955 [3]. In the period from 1955-1975 different important cardiovascular surgical groups 
published their reports about surgical treatment of carotid stenosis in symptomatic patient 
using different reconstructive procedures. Eastcot, Pickering and Rob in 1954 reported 
resection of carotid bifurcation and internal to common carotid artery bypass, while 
DeBakey, then Row and Cooley performed carotid endarterectomy (CEA) – plaque removal 
instead of bypass [4, 5, 6, 7]. Afterwards idea of plaque removal instead of bypass was 
accepted widely, and its’ efficacy in stroke prevention was later proved in multiple trials [8, 
9, 10, 11, 12, 13].   
Still, diverse pathologies of carotid artery were treated even before this obsession with 
carotid stenosis. French surgeon LeFevre used external carotid artery for flow restoration in 
case of traumatic lesion of internal carotid artery [14]. In the golden fifties, when carotid 
surgery was born, other authors reported their experience in treatment of carotid aneurysms 
[15, 16]. Although Dimitza used resection and reanastomosis, Beall had to use graft 
interposition. In this position authors were using autologous and synthetic graft with 
similar results; however in region susceptible to infection, autologous graft was preferred. 
DeBakey also reported his results in usage of graft replacement in case of carotid trauma 
[17]. In the beginning of treatment of carotid stenosis there were also reports of different 
 The Author(s). Licens e InTech. i  ch pter is distributed under the terms of the Cr ative C mmons 
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techniques similar to those described in trauma and aneurysmatic disease. Dehnman et al 
treated carotid occlusion with homograft while Doyle et al used saphenous vein for 
treatment of carotid stenosis [18, 19]  
On the other side, endarterectomy as surgical method for the treatment of stenotic arterial 
lesions was performed on superficial femoral artery, by Dos Santos, and later with extensive 
usage of Heparin it gain more success and showed its role in aorto-iliac position [20, 21]. 
Further experience showed its’ excellent effect in focal stenotic lesions in vessels with large-
caliber and high-flow rate. In everyday clinical practice this technique has proved efficient 
in patients with localized disease limited to the distal aorta or proximal iliac arteries and 
distal common femoral artery obstructing deep femoral artery orifice (profundoplasty) [22, 
23, 24]. On the contrary in extensive atherosclerotic pattern that are more frequent in clinical 
practice, endarterectomy is technically demanding with poor long term results [25]. Later 
trough history, short lesions were preferably treated by endovascular means, leaving bypass 
reconstruction for longer ones, while isolated endarterectomy is becoming almost forgotten 
except in carotid bifurcation. It is rarely recognized in the literature that in some, not 
frequent, situations endarterectomy in stenotic carotid artery is not possible or it might be 
jeopardized. What are modes of reconstruction of carotid artery when CEA fails or is not 
possible? If bypass or graft replacement is alternative in peripheral occlusive disease, should 
we apply it in carotid position as well in situations when extensive disease is encountered or 
technical challenge happens? 
2. Aim of the chapter 
The aim of this chapter is to show results and experience of a single high volume center in 
usage of synthetic graft in the treatment of extensive carotid atherosclerotic disease and to 
analyze published results related to this topic. 
3. Material and methods 
Clinic for Vascular and Endovascular Surgery of the Serbian Clinical Center is located in 
Belgrade, Serbia, and it was part of the Second surgical clinic, the cradle of cardiovascular 
medicine in the former Yugoslavia. First vascular procedures were performed in its’ 
facilities in the sixties (1966) by outstanding pioneers of this, in that time, new branch of 
surgery – V. Stojanovic and B. Vujadinovic. Figure 1 (A and B). Further development of this 
institution was supported by the fact that it becomes educational and referral center. 
Intensive cooperation with leading world centers of excellence, sending its practitioners for 
education and organizing demonstrational operations in own facilities contributed to 
popularization and development of cardiovascular surgery in the former Yugoslavia, 
Balkans and Eastern Europe with consequent progress in treatment of cardiovascular 
patients in this institution. Later S.Lotina, (Figure 1 - C) successor of Stojanovic and 
Vujadinovic, has significant role in development of vascular surgery in this institution, since 
he struggled for segmentation of cardiovascular surgery in the late eighties and middle 
nineties and eventually achieved expansion of independent vascular department with 
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surgeons and angiologists dedicated to this field. Later, Lazar Davidovic, (Figure 1 - D) one 
of his pupils, becomes new leader of this department accomplished to improve it to the level 
of the clinic. After finishing his education with fellowship at Pitié-Salpêtrière hospital in 
Paris, under the service of Prof Eduard Kieffer, where he improved his experience in aortic 
and carotid surgery, adopting eversion technique, L. Davidovic brought new modern 
perspectives in the diagnosis and treatment of vascular patients not only in this institution 
but rather in the whole country of Serbia.  Since then the number of carotid and aortic 
procedures is annually increasing in this institution reaching almost 600 carotid and almost 
500 aortic in the year 2011, with sensible and gradually introduction of endovascular 
procedures (carotid, peripheral stenting and endovascular repair of aortic pathology) 
according to published results, guidelines recommendation and available financial support 
of national health care system.  
 
Figure 1. Leaders of development of vascular surgery in Serbian Clinical Centre in last 60 years. A. 
Vojislav Stojanovic (1955-1971) B. Borislav Vujadinovic (1971-1985) C. Slobodan Lotina (1985-2002) D. 
Lazar Davidovic (2002- still leading Clinic for Vascular and Endovascular Surgery) 
In the period from January 2003 to October 2006, at the Clinic for Vascular and 
Endovascular Surgery of the Serbian Clinical Centre, 1250 procedures due to carotid artery 
stenosis in 1127 patients were performed. Carotid stenosis was repaired by eversion or 
conventional endarterectomy (CEA) and synthetic graft (Dacron®) interposition in 987 (78, 
96 %), 205 (16, 4 %) and 58 (4, 64 %) patients respectively. We retrospectively analyzed 
prospectively gathered data related to the subgroup of patients operated with graft 
replacement.  
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Indications for conventional EA with usage of protective intraluminal shunt were 
contralateral occlusion, recent stroke or transitory ischemic attack and intraoperative stump 
pressure below 40mmHg. These patients were excluded from this analysis. Other patients 
were operated with eversion technique. Eversion EA was performed in the same manner as 
described elsewhere in the literature [26]. 
Indications for graft replacement (GR) were: extensive atherosclerotic disease proximal 
and/or distal to carotid bifurcation revealed intraoperatively during dissection or 
preoperatively by means of ultrasound, digital subtraction angiography (Figure 3.) or 
multidetector computed tomography; long segment of thrombotic surface after EA; bad 
quality of arterial wall after EA; inadequate end of the endarterectomy cleavage; any other 
technical problem that could endanger the success of procedure. Decision for GR was made 
by operating surgeon. 
GR was performed after complete resection of carotid bifurcation and its removal. Dacron 
graft of 6 or 8 mm in diameter was used depending on the ICA and CCA diameter. Initially 
anastomosis between the graft and ICA was made, in the continuous fashion, “parachute” 
technique, with Prolene 6-0 suture. Upon finishing the anastomosis clamp was removed 
proximaly on the synthetic graft in order to verify anastomotic compatibility. Afterwards 
proximal anastomosis between CCA and synthetic graft was sutured with Prolene 5-0 in the 
same fashion. Flushing and air removal is of outmost importance before declamping since 
there is in-line flow directly to endocranial vascular bed without any patent branch. 
Reattachment of ECA was performed selectively according to its quality, position and 
already spent time for GR (Figure 2 and 3.). 
 
Figure 2. Schematic presentation of carotid graft replacement. A. Resection of carotid bifurcation 
B. Suturing distal anastomosis C. Suturing proximal anastomosis 
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Figure 3. Intraoperative image of final graft reconstruction A. Dacron graft interposition B. Dacron graft 
interposition with reimplanted external carotid artery 
In this period of time (2003-2006) cervical plexus block was introduced for carotid surgery in 
our institution, and consequently we changed the indications for conventional 
endarterectomy and shunt usage performing it only in case of neurological deterioration of 
the patient during carotid cross clamping. However patients treated with conventional EA 
with extensive atherosclerotic disease were not analyzed in this paper and GR was 
performed without usage of the intraluminal shunt. 
Among 1045 procedures performed in 956 patients there were 987 (94, 45%) treated with 
eversion EA and 58 (5, 55%) with GR. After excluding patients treated with conventional 
and eversion EA, we retrospectively analyzed preoperative, intraoperative and 
postoperative data of the patients treated with GR in order to investigate results of this 
alternative procedure and to try to define optimal indications for its’ usage. After analyzing 
initial results deeper investigation was performed by dividing group of patients treated 
with GR in two groups according to the indication and decision to perform GR:  
Group A, when decision to perform GR was made according to the ultrasonography exam 
and intraoperative findings before any attempted EA;  
Group B when GR was made after failed EA as a bailout procedure.  
In the preoperative data we analyzed age, sex, co-morbid conditions and preoperative 
ultrasound descriptions. All patients were preoperatively examined by ultrasonography 
means, describing quality and length of the plaque. All exams were made by experienced 
ultrasonographer. The quality of plaque was described as lipid, fibrous or calcified with or 
without present ulceration. The length of the plaque was defined as the longitudinal extent 
of the plaque narrowing arterial lumen for 30% and more. Plaques longer than 4cm were 
named as long.  
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B. Suturing distal anastomosis C. Suturing proximal anastomosis 
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Figure 3. Intraoperative image of final graft reconstruction A. Dacron graft interposition B. Dacron graft 
interposition with reimplanted external carotid artery 
In this period of time (2003-2006) cervical plexus block was introduced for carotid surgery in 
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performed without usage of the intraluminal shunt. 
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initial results deeper investigation was performed by dividing group of patients treated 
with GR in two groups according to the indication and decision to perform GR:  
Group A, when decision to perform GR was made according to the ultrasonography exam 
and intraoperative findings before any attempted EA;  
Group B when GR was made after failed EA as a bailout procedure.  
In the preoperative data we analyzed age, sex, co-morbid conditions and preoperative 
ultrasound descriptions. All patients were preoperatively examined by ultrasonography 
means, describing quality and length of the plaque. All exams were made by experienced 
ultrasonographer. The quality of plaque was described as lipid, fibrous or calcified with or 
without present ulceration. The length of the plaque was defined as the longitudinal extent 
of the plaque narrowing arterial lumen for 30% and more. Plaques longer than 4cm were 
named as long.  
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After removing atherosclerotic plaque from internal carotid artery (ICA) and common 
carotid artery (CCA) its’ quality (morphology) and length were assessed too. From 
intraoperative data we used the intraoperative length of atherosclerotic disease, reasons to 
perform GR (before any attempt to perform eversion or after attempted eversion), cross 
clamping time and restoration of external carotid artery flow.  
Postoperative data were related to the neurological outcome and mortality rate as well as 
early surgical (hemorrhage, cranial nerve lesions, and wound infection) and cardiac 
complications. All patients were followed for one month and yearly thereafter with clinical 
and ultrasound examination.  
4. Results 
Among treated patients significant number was symptomatic - 30 (51, 72 %) patients with 
previous transitory ischemic attack (12 – 40%), ocular symptoms (2 – 6, 66%) or stroke (16 – 
53, 33%). Demographic characteristics of the patients and symptoms distribution were 
presented in the Table 1. There was no significant difference in terms of co-morbid 
conditions between the groups. 
 




Number of patients 58 (100) 40 (68.96) / 18(31.04) 
Age 65.55 66.8 / 64.3 
Male 50 (86.2) 34 (85) / 16 (88.88) 
Arterial Hypertension 48 (82.75) 35 (87.5) / 13 (72.22) 
Smoking 40 (68.96) 28 (70) / 12 (66.66) 
Obesity 10 (27.24) 7 (17.5) / 3 (16.66) 
Diabetes 32 (55.17) 23 (57.5) / 9 (50) 
Angina pectoris 24 (41.3) 18 (45) / 6 (33.33) 
Myocardial infarction 15 (25.86) 11 (27.5) / 4 (22.22) 
Aortic disease 5 (8.62) 4 (10) / 1 (5.55) 
Peripheral disease 9 (15.51) 6 (15) / 3 (16.66) 
Previous CABG 8 (13.79) 5 (12.5) / 3 (16.66) 
Previous aortic procedures 2 (3.44) 2 (5) / 0 
Previous peripheral procedures 0 0 
Symptoms  
Asymptomatic 28 (48.27)  
Symptomatic 30 (51.73)  
Transitory ischemic attack                              12 ( 40)
Ocular symptoms                                               2 ( 6.66) 




Table 1. Demographic characteristic of the patients and preoperative symptoms  
There was no significant difference between ultrasonography and intraoperative findings in 
the group A. There was significant difference between ultrasonography and intraoperative 
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findings of the plaque length on the CCA and ICA among patients of group B. There was 
significant number of patients with plaque length of 4cm and more in the CCA, described in 
the ultrasonography exam and found intraoperatively. Tables 2 and 3  
 









7 (17.5%) / 
tructio5 (12.5%) 
5 (12.5%) / 
0 
P > 0.05 
Lipid plaque/ 
with ulceration 
5 (12.5%) / 
1 (2.5 %) 
9 (22.5%) / 
1 (2.5 %) 
P > 0.05 
Calcified plaque/ 
with ulceration 
6 (15%) / 
19 (48%) 
11 (27.5%) / 
14 (34.5%) 
P < 0.05 
CCA plaque length> 4cm  19 (48%) 22 (55%) P > 0.05 
ICA plaque length> 4cm 12 (29.5%) 19 (48%) P > 0.05 
 
Table 2. Comparison of ultrasonography and intraoperative findings in the patients of the group A 
 
Plaque morphology Ultrasonography Intraoperative 
findings 
P 






4 (22.2%) / 
1 (5.06) 
2 (11%) / 
0 
P > 0.05 
Lipid plaque/ 
with ulceration 
2 (11%) / 
0 
2 (11%) / 
1 (5.06%) 
P > 0.05 
Calcified plaque/ 
with ulceration 
3 (16.6 %) / 
8 (44.44%) 
6 (33.33 %) / 
7 (38.88%) 
P > 0.05 
CCA plaque length> 4cm 6 (33.3%) 10 (55.55%) P > 0.05 
ICA plaque length> 4cm 0 3 (16.66%) P<0.05 
 
Table 3. Comparison of ultrasonography and intraoperative findings in the patients of the group B 
Intraoperative data were presented in the table 4. Among 58 patients, 22 (37.93%) were 
operated in conditions of general anesthesia and 26 (62.07%) under cervical plexus block. 
Mean cross clamping time was measured and presented in Figure 2. There was significantly 
longer cross clamping time when GR was made after attempted EA. ECA flow restoration 
was made in 9 (15.6%) patients with intraoperative decision of the operating surgeon 
according to the quality of ECA, its’ position related to the implanted graft and elapsed time 
of the procedure. Reimplantation of ECA did not influence on neurological complication 
rate. 
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Early postoperative recovery was uneventful in 36 patients (95%). Early death was reported 
in 2 patients (5%), due to fatal stroke in the early postoperative time. More one patient had 
transitory ischemic attack (2,5%) and one had minor stroke (2,5%). Total rate of neurological 
complications is 7.5%. Comparison of the neurological complications between the groups 
found higher rates when EA was unsuccessful and GR performed as a bail out procedure. 
Permanent cranial nerve injuries were reported in 1 patient (2.5%). There was neither early 
myocardial infarction nor death based on any other cause in this series.  
Patients were followed by means of ultrasonography one month after the procedure and 
yearly thereafter. Mean follow up time was 32 months. Two patients were lost from follow 
up while 4 patients (10.52%) died during this period of time. Restenosis of less than 75% was 
reported in 2 patients (5.26%), restenosis of 75-99% was found in 1 patient (2.78%) 
successfully treated with carotid stenting (Figure 5). In one patient total occlusion of 
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Figure 5. Restenosis at the proximal anastomosis (A) resolved with carotid stenting (B) 
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5. Discussion 
There is no doubt that, over all, endarterectomy is the optimal technique for surgical 
repair of carotid stenosis. This is the only location where EA is the preferable method 
nowadays. Choice of EA (conventional or eversion) might cause some discussion between 
vascular surgeons however the last meta-analysis gave slight advantage to eversion, which 
was also shown by randomized trial in our institution [27, 28]. Previous Meta analysis 
showed no difference between the two techniques [27]. The former includes a standard 
longitudinal carotid arteriotomy with or without patch angioplasty, whereas the second 
encompasses an oblique transection and eversion of the internal carotid artery and its’ 
reimplantation into the common carotid artery [29, 30, 31]. Regarding the carotid artery 
closure after conventional EA, carotid patch angioplasty is preferable to primary closure 
[32]. 
Conventional EA requires usage of graft material that is extending procedure and expose 
patient to the risk of infection [33]. Eversion EA on the other side does not provide 
sufficient insight in to the complete endarterectomized surface in the zone at the end of 
the removed atherosclerotic plaque. Also preparing carotid bifurcation for eversion EA 
requires its complete deliberation from surrounding tissue which might increase the risk 
of distal embolizations. Elongated internal carotid artery makes patch suturing more 
complex while shunt placement in these situations is raising the difficulties. Redundant 
ICA might simplify eversion EA on the other side. Both of these techniques are related to 
some advantages and disadvantages including surgeons’ familiarity as a specific one.  
Both of the techniques requires volume of patients in order to achieve good results what 
might influence the diverse adoption between the teams. According to one multinational 
registry there is difference in the usage rate of these techniques – in eight European 
countries EA was performed without patch (34%), with patch (40%) or with eversion 
(26%). Finally, guidelines of the most important and leading societies are leaving the 
choice between the two techniques to the operating surgeon [32, 34]. Does it mean that 
any procedure that removes atherosclerotic plaque from carotid bifurcation and restores 
flow in a short and long term would be effective in stroke prevention? The similar theory 
said M.E. DeBakey sixty years ago before his first carotid procedure. DeBakey reasoned 
that, since endarterectomy and graft replacement in other arteries could be performed, the 
carotid artery should not be an exception [35].  
Carotid stenosis is most frequently localized at the carotid bifurcation leaving proximal 
and distal segments free from disease providing suitable conditions for endarterectomy. 
Extension of the atherosclerotic process towards proximally or distally might make 
endarterectomy cumbersome and risky, while multiple severe atherosclerotic changes at 
different levels of supra-aortic branches require anatomical or extra-anatomical bypass 
procedure. Group of patients analyzed in this chapter belongs somewhere between these 
two patterns of carotid disease – not enough extensive for anatomical bypass through 
sternotomy while substantially extensive and challenging for eversion EA. 
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From technical point of view atherosclerotic process that extends proximally and/or 
distally aggravates endarterectomy jeopardizing the procedure. Initial problem is carotid 
clamping. It is necessary to extensively dissect internal and common carotid artery in order 
to provide safe clamping. Clamping at inadequate location of diseased artery might cause 
plaque rupture with consequent prone to thrombosis causing perioperative 
embolizations. Also, clamping at inadequate location could cause incomplete EA causing 
thrombosis especially at the internal carotid artery location. Preventing incomplete EA in 
this situation requires additional dissection which is more challenging during clamped 
and transected carotid artery, it prolongs cross clamping time and might stress 
inexperienced surgeon provoking other mistakes. Reaching healthy zone is important 
likewise for shunt users in order to prevent placing a shunt through atherosclerotique 
plaque inducing distal embolizations. Once reaching the conform clamping zone we are 
faced with technicaly demanding extensive EA. In case of eversion technique problems 
are visualization of the end of the plaque zone, adequate flushing of the left surface and 
removal of small residual intimal particles that are prone to mobilization causing distal 
embolizations [36]. Extensive dissection of internal carotid artery and its deliberation from 
surrounding tissue facilitate its eversion. On the contrary, common carotid artery is even 
more difficult to evert through the whole circumference since the posterior wall is fixed 
with the external carotid artery. Due to that flexibility of common carotid artery depends 
on deliberation of external carotid artery from surrounding tissue too. In case of extensive 
athersoclerosis of common carotid artery and average to minimal process on internal 
carotid artery it is advisible to transect common carotid artery proximal from its’ 
bifurcation instead of transecting internal carotid artery. This techniqe provides easier EA 
of common carotid artery in a longer segment [7]. Another technical possibility to deal 
with extensive atherosclerotic disease in common carotid artery could be semi closed 
endarterectomy by using Vollmars rings. Finally, for those who preffer conventional 
technique the very process of EA is quite easier with adequate visualisation of the end of 
the plaque zone, however, finally the Achille heel of this method is long patch 
anastomosis that is technicaly demanding and more prone to neointimal hyperplasia or 
false aneurysm. Anastomotic bleeding on the long patch is another technical difficutly 
especialy when using intraluminal shunt. Upon removing the shunt, brain perfusion is 
reduced until complete haemostasis is provided making declamping safe. Loosing time on 
resolving anastomotic bleeding could cause ishemic brain injury. Overcoming all these 
technical difficulties does not guarantee sucess since long endarterectomy is leaving long 
thrombogenic surface prone to in situ thrombosis or distal embolizations jeopardizing the 
results of the procedure regardless to excellent surgical technique.  
All these difficulties were encountered in peripheral vascular surgery inducing usage of 
different conduits in the reconstructive bypass procedures; similar was done in carotid 
surgery although less frequently. Bypass in this location could have a good long term 
potential since it is connecting two healthy arteries with high blood flow and loaded 
recipient vascular bed, like cerebral, which is inducing low resistance. Still low number of 
publications is describing this technique in the last 30 years with usage of different conduits. 
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Consequently in the two most respected guidelines for treatment of carotid stenosis this 
option is not mentioned. However a short review of the published data related to this 
technique is given below with some technical remarks from the authors of this chapter. 
In 1979 M.E.Debakey published his experience in usage of synthetic graft for repair of 
carotid artery injury [37]. In the same year Cormier and all started to use this type of 
reconstruction reporting their experience eight years later [38]. Among 62 treated patients 
54 (87%) were treated due to extensive atherosclerotic disease, with 5% stroke rate and 
97% patency in the 23 months long term follow up. Later, different types of reconstruction 
were reported using various conduits. Camiade and all used PTFE graft suture with side 
to end proximally and end to side anastomosis distaly [39]. This technique minimizes 
dissection of carotid bifurcation and preserves patency of external carotid artery. Authors 
performed this procedure in 110 patients, indicated it in case of extensive atherosclerotic 
disease in 45 (41%), while using it also for reconstruction in case od restenosis (16.4%) or 
kinking (26.4%). There were some other authors reporting usage PTFE graft with similar 
patency of 95-97% in the long term [40, 41]. The only author that used Dacron graft was 
Valdeniz with results comparable to those published with PTFE [42]. Autologous 
saphenous vein was also reported by various authors, some of them complaining on high 
restenosis rate. French authors are reporting good early and long term results [43, 44, 45]. 
In 212 patients treated due to extensive atherosclerotic disease (76%), restenosis (5.6%), 
kinking (8.49%) and aneurysm (4.24%) they reported 5% stroke rate and 96% patency after 
average 104 months of follow up. On the other side according to the Leicester group 
saphenous vein is prone to early restenosis in this position even though they performed 
different anastomotic techniques [46]. According to the diameter of the vein graft and 
common carotid artery they located anastomosis at the lateral wall of common carotid 
artery, at the origin of internal carotid artery or at the origin of external carotid artery 
after its’ exclusion. After average follow up of 60 months patency rate was 83% with 
significant incidence of restenosis. According to opinion of the authors of this chapter 
vein graft could be perfect for this procedure, however one might expect misfit of the 
calibers. Additionally harvesting this graft could be time consuming if so if the graft 
replacement is performed as a bailout procedure it might prolong cross clamping time 
and procedure. It is not convenient for carotid procedures performed in cervical plexus 
block and finally saphenous vein is important conduit for coronary revascularization and 
should be preserved for that occasion as well. This conduit could be unavailable in 
patients with varicose syndrome and previous coronary revascularization. Latest 
publication is from W. Moore reporting 17 years of experience using both synthetic and 
saphenous vein grafts with satisfying results [47]. 31 PTFE and 10 saphenous grafts were 
followed for 50 months with patency of 90% and 80%, respectively. Carotid graft 
replacement is already proved procedure in some other pathology like carotid artery 
aneurysm and restenosis [48, 49]. 
Summarized published data show 613 carotid procedures where bifurcation was 
reconstructed with GR. In all these publications the most frequent indication for graft usage 
was extensive atherosclerotic disease with involvement of common or distal internal carotid 
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54 (87%) were treated due to extensive atherosclerotic disease, with 5% stroke rate and 
97% patency in the 23 months long term follow up. Later, different types of reconstruction 
were reported using various conduits. Camiade and all used PTFE graft suture with side 
to end proximally and end to side anastomosis distaly [39]. This technique minimizes 
dissection of carotid bifurcation and preserves patency of external carotid artery. Authors 
performed this procedure in 110 patients, indicated it in case of extensive atherosclerotic 
disease in 45 (41%), while using it also for reconstruction in case od restenosis (16.4%) or 
kinking (26.4%). There were some other authors reporting usage PTFE graft with similar 
patency of 95-97% in the long term [40, 41]. The only author that used Dacron graft was 
Valdeniz with results comparable to those published with PTFE [42]. Autologous 
saphenous vein was also reported by various authors, some of them complaining on high 
restenosis rate. French authors are reporting good early and long term results [43, 44, 45]. 
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kinking (8.49%) and aneurysm (4.24%) they reported 5% stroke rate and 96% patency after 
average 104 months of follow up. On the other side according to the Leicester group 
saphenous vein is prone to early restenosis in this position even though they performed 
different anastomotic techniques [46]. According to the diameter of the vein graft and 
common carotid artery they located anastomosis at the lateral wall of common carotid 
artery, at the origin of internal carotid artery or at the origin of external carotid artery 
after its’ exclusion. After average follow up of 60 months patency rate was 83% with 
significant incidence of restenosis. According to opinion of the authors of this chapter 
vein graft could be perfect for this procedure, however one might expect misfit of the 
calibers. Additionally harvesting this graft could be time consuming if so if the graft 
replacement is performed as a bailout procedure it might prolong cross clamping time 
and procedure. It is not convenient for carotid procedures performed in cervical plexus 
block and finally saphenous vein is important conduit for coronary revascularization and 
should be preserved for that occasion as well. This conduit could be unavailable in 
patients with varicose syndrome and previous coronary revascularization. Latest 
publication is from W. Moore reporting 17 years of experience using both synthetic and 
saphenous vein grafts with satisfying results [47]. 31 PTFE and 10 saphenous grafts were 
followed for 50 months with patency of 90% and 80%, respectively. Carotid graft 
replacement is already proved procedure in some other pathology like carotid artery 
aneurysm and restenosis [48, 49]. 
Summarized published data show 613 carotid procedures where bifurcation was 
reconstructed with GR. In all these publications the most frequent indication for graft usage 
was extensive atherosclerotic disease with involvement of common or distal internal carotid 
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artery – 328 procedures (53.5%). Other indications were carotid recurrent stenosis, technical 
failure of attempted EA, stenosis after radiation therapy, carotid aneurysm and carotid 
stenosis associated with kinking. Among 613 carotid stenosis treated with GR, 290 (47,3%) 
procedures were performed with PTFE graft, 272 (44,37%) with saphenous graft and 51 
(8,31%) with Dacron. Extensive and detailed information regarding published data are 
shown in the Table 4. 
6. Conclusion 
When it comes to carotid stenosis, EA is the method of choice in majority of patients. Small 
subgroup of patients had extensive carotid atherosclerotic disease that involves common or 
internal carotid artery in a segment longer than 4cm. In these situations modification of 
surgical procedure is necessary since EA might be jeopardized. Optimal scenario would be 
to assess extension of atherosclerotic process preoperatively through ultrasonography or 
MSCT angiography or intraoperatively during dissection of carotid arteries. In case of 
extensive atherosclerotic process, decision to perform carotid graft replacement without any 
attempt of EA could simplify procedure, shorten cross clamping time and avoid technical 
and thromboembolic complications. Conduit choice is the matter of operating surgeon. 
Upon clamping and resecting diseased segment, suturing distal anastomosis first is 
recommendable in order to provide easier manipulation and better visualization of 
anastomotic line. Next step is suturing the proximal anastomosis then flushing and finally 
carotid declamping. Reimplantation of external carotid artery is not mandatory and the 
decision should be made as the preference of the surgeon. Efforts to perform EA even in 
case of extensive disease could be effective especially in experienced hands, however in case 
of any doubts in wall quality or end of the plaque zone, graft replacement should be 
performed before flow restoration in order to prevent fatal complications that this procedure 
carries.   
There is not enough evidence to provide any accurate criteria for usage of carotid graft 
replacement instead of endarterectomy. This chapter showed results, experience and 
technical details of a single high volume center and presented not so reach published 
material. Decision to perform graft replacement should be made individually according to 
anatomy and morphology of carotid disease. Wide surgical experience affords expertise and 
improves individual decision making. 
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1. Introduction 
Technical advances in Vascular Surgery have led to an increased use of prostheses (grafts, 
patches, stents, stent grafts etc.) and improved results for the patient. Despite routine 
antibiotic prophylaxis, infection, although rare, remains a serious complication, with 
catastrophic consequences. Vascular infections are divided into 3 groups according to 
Szilagyi (Table 1.), depending on the extent of the inflammation: the superficial, the deep 
and the mixed type.[1] Samson (Table 1.), as well as Karl and Storck (Table 1.) , have 
modified the widely used classification system of Szilagyi.[1-3] While the superficial type is 
restricted to the skin and subcutaneous tissue, the deep infection involves the vessels or a 
prosthetic graft. The mixed type of vascular infection is the combination of the above types 
affects all the tissue layers and can produce trauma disruption. Vascular infections can be 
classified by appearance time into: a) early (<4 weeks after graft implantation) and b) late (>4 
weeks). Samson’s and Karl’s modifications take into consideration further clinical 
parameters, which define the treatment (Table 2.). [2,3] When infection involves a graft 
anastomosis or the suture line of a patch, there is high risk of vessel rupture, septic 
hemorrhage or pseudoaneurysm formation. [4-6] Other serious complications are septic 
thrombosis, endocarditis, etc. [7] In severe cases, treatment can be problematic and mortality 
remains high, despite the use of antibiotics and surgical treatment. Keys to successful 
outcome include early and accurate diagnosis, identification of the infecting organism, and 
extent of graft infection, administration of culture-specific antibiotic therapy, and excision or 
replacement of the infected graft. 
2. Epidemiology 
The reported incidence of infection involving vascular prosthesis varies, occurring after 
0.2% to 5% of vascular procedures . [4] The long - term incidence is possibly higher than that 
reported, since some graft infections (e.g. aortic graft infections) develop several years after 
implantation . [8] 
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Table 1. Classification of vascular graft infections 
 
Grade Clinical findings Recommendation 
Szilagyi I, Samson I
 
Infection involves only cutis Conservative treatment 
Szilagyi II, Samson II, 
Karl I 
Cutis/subcutis infection without 
graft involvement 
a) graft preservation combined with 
VAC 
b) graft excision 
Szilagyi III, Samson 
III, Karl II 
Deep graft infection without 
involvement of anastomosis or 
suture line 
a) graft preservation combined with 
VAC 
b) graft excision 
Szilagyi III, Samson 
IV, Karl III-IV 
Deep graft infection with 
involvement of anastomosis or 
suture line 
a) graft excision 
b) graft preservation combined with 
VAC 
Szilagyi III, Samson 
V, Karl V-VI 
Deep graft infection associated 
with complications (bleeding, 
thrombosis, suture aneurysm) 
graft excision 
Table 2. Therapeutic recommendations depending on the infection grade 
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Incidence of vascular infections is influenced by patient’s general condition, the type of the 
procedure, the coexistence of other simultaneous inflammation sites, the type of 
prophylactic antibiotics given perioperatively and by prolonged operative time and hospital 
stay . [9-13] Infections are much more frequent in the groins (60% of cases), in grafts placed 
in a subcutaneous tunnel and after emergency cases (e.g. acute arterial ischemia). Infection 
can also develop after percutaneous stent angioplasty but in low rates (0.5%). [14,15] 
Early graft infections usually affect extracavitary grafts, while majority of late infections 
involve cavitary (i.e., aortic) grafts. [16] 
3. Pathogenesis 
Exposure of vascular grafts to bacteria, irrespective of source, may result in colonization and 
subsequent infection. Microorganisms can result in clinical infection most commonly, 
perioperatively, during surgical implantation or through the surgical wound. The most 
common mechanisms of infection are: break of aseptic techniques in the operating room and 
contact of the graft with patient’s endogenous flora harboured in lymphatics rupturing 
intraoperatively, sweat glands or mucosas. Intraoperative injury of gastrointestinal or 
genitourinary tract, diseased arterial wall, healing problems of surgical wound and 
reoperations can result in graft infection. [4] 
Bacterial contamination of the prosthesis via a hematogenous route is rare, though urinary 
tract infections, infected intravascular catheters, pneumonia or other remote tissue infections 
(e.g. infected foot ulcer) increase the risk of graft infection. Bacteremia can result in graft 
infection, years after the implantation, especially in elderly patients with altered immune 
status. 
Moreover, erosion of a prosthetic graft through the skin or into the gastrointestinal or 
genitourinary tract can lead to an infection. GEE/GEF can develop due to pulsatile pressure 
transmitted via an aortic graft to the overlying adherent bowel, usually the third part of the 
duodenum. This can be prevented by coverage of the graft by adjacent omentum at the end 
of the procedure. A graft-cutaneous fistula by erosion through intact skin is most commonly 
the result of a low-grade infection caused by S. epidermidis.  
Finally, grafts can get contaminated by a contiguous infectious process as a result of an 
adjacent infection (e.g. diverticulitis, infected lymphocele). 
 Predisposing factors for vascular infection are the use of prosthetic grafts, procedures in the 
groins, local or systemic septic conditions, while the predicting factors are patient’s immune 
status, graft’s characteristics, prolonged hospital stay , bacterial virulence or resistance to 
antibiotics. Additionally, reoperations, long or emergency procedures, faulty sterile surgical 
technique, postoperative complications (such as hematoma, graft thrombosis) and 
concomitant urological or biliary and colon operations contribute to increased rates of 
vascular infections. [17] 
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4. Bacteriology 
Staphylococci (Staphylococcus aureus and coagulase negative staphylococci) account for more 
than 75% of vascular device-related infections. In fact, S. aureus is the most prevalent 
pathogen. Graft infections due to S. epidermidis or gram-negative bacteria have increased in 
frequency. Less frequently, microorganisms of the skin flora, such as streptococci and 
Propionibacterium acnes, are isolated.  
Gram-negative bacteria such as Pseudomonas, E. coli, Klebsiella, Enterobacter, and Proteus 
species are particularly virulent, followed by high rates of anastomotic disruption. This can 
be explained by their ability to produce toxins, such as elastase and alkaline protease, which 
can decompose the arterial wall. [18,19] 
MRSA (Methicillin-resistant S. aureus) vascular infections present with increased incidence. 
[20] Fungal infections  are rare and develop usually in immunosuppressed patients. 
 Early infections are usually caused by especially virulent microorganisms, such as S. 
aureus, Streptococcus faecalis, E. coli, Pneumococcus, Klebsiella and Proteus. Late infections 
are the result of low-virulence microorganisms such as S. Epidermidis.  
5. Clinical manifestations 
Clinical manifestations vary according to the localization of the vessel that is involved. Graft 
infections in limbs (e.g. femoropopliteal graft) present with edema, cellulitis or with a 
pulsatile mass, in case anastomotic rupture and pseudoaneurysm formation. According to 
Szilagyi, vascular infections can be classified by relationship to postoperative wound 
infection. Graft contamination in the abdominal (Table 3.) or thoracic cavity, usually 
presents with systematic sepsis, aortoenteric, and aortobrochial or aortooesophageal fistula. 
Symptoms in early infections can be fever, leukocytosis and perigraft purulence. 
Patients with aortic grafts and gastrointestinal bleeding should be investigated for GEE. 
[21,22] Bacteremia develops in advanced graft infections. Graft infection due to S. 
epidermidis typically presents months to years after graft implantation with anastomotic 
aneurysm, graft-cutaneous sinus tract or perigraft cavity with fluid. Vascular Surgeon 
should, also, look for other sources of infection, (e.g. feet or urinary infections). 
6. Diagnosis 
6.1. Laboratory testing 
Early diagnosis is crucial for treatment and for prevention of septic complications that can 
threaten the affected limb or even patient’s life. It is based on physical examination  and 
imaging modalities. Blood tests results are non-specific for vascular infection, with low 
diagnostic value. Elevated WBC count with left shifted differential, increased erythrocyte 
sedimentation rate or high levels of CRP can be found during the acute phase. Blood 
cultures are rarely positive (˂5%) but such findings, in addition with high fever, are markers 
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of advanced infection and sepsis. In these cases, early hospital admission and treatment are 
essential. Laboratory tests should include cultures from other sites of infection and stool 
guaiac, in case GEE is suspected. 
 
Table 3. Classification of aortic graft infection (Bandyk 1991) 
6.2. Vascular imaging  
Vascular imaging is of crucial significance in the diagnosis and treatment planning of 
vascular infections. Imaging modalities that are useful for diagnosis are ultrasonography, 
CT Angiography, MR Angiography, endoscopy or functional radionuclide imaging (indium 
111-labelled leukocytes). The combination of anatomic and functional vascular imaging 
techniques shows high sensitivity (80% to 100%) and specificity (50% to 90%) in 
identification of infection. 
Plain radiographs are of limited value, providing information only in the case of prosthesis 
misplacement or dislocation. 
Color duplex scanning is a readily available imaging technique, reliable for diagnosis of 
perigraft fluid collection, which can be differentiated from anastomotic pseudoaneurysms, 
especially in extracavitary infections. Imaging of abdominal cavity or aortic grafts is not 
accurate in obese patients. Graft patency can be easily examined. 
Contrast-enhanced CT is the preferred imaging technique for abdominal or thoracic aorta 
graft infections. Signs of abnormal fluid or gas collections around the prosthesis (beyond 2-3 
months of implantation) or false aneurysm formation are suggestive of infection. Loss of 
normal retroperitoneal tissue planes or vertebral osteomyelitis in a patient with an aortic 
graft indicates a vascular infection. CT-guided aspiration is being increasingly used to 
differentiate perigraft abcesses from seromas. 
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MRA is an alternative modality to CTA, with equal specificity or sensitivity. It can also 
differentiate perigraft fluid from adjacent fibrosis. Gadolinium is less nephrotoxic in patients 
with renal insufficiency. However, it is contraindicated in patients with electrophysiological 
devices. The presence of metallic materials may cause artefacts that compromise image quality. 
The use of arteriography is useful in the identification of anastomotic aneurysms or other 
graft complications (e.g. graft rupture) and for the evaluation of the vascular tree before 
revascularization planning. It should be a routine examination in hemodynamically stable 
patients with graft infection unless CT or MRI scans give the above type of information. 
Functional White Blood Cell Scanning is indicated in special cases. 99mTc-labelled white 
blood cells, 111In or gallium scintigrams are most commonly used along with MRI and CT 
to define the extent of graft involvement. Positive predictive value of the functional imaging 
scans ranges between 80% to 90% in the detection of graft infection. False-positive results 
are not uncommon during the early postoperative period.  
Endoscopy is very useful in cases of suspected secondary aortoenteric erosion or fistula and 
is an emergency procedure in patients with massive gastrointestinal bleeding where it can 
be performed in the operating theatre, with the patient prepared for operation. It is 
important is to visualize the third and fourth part of duodenum and rule out other sources 
of gastrointestinal bleeding. Though, an aortoduodenal fistula cannot be excluded by 
negative findings. 
7. Operative findings 
Operative exploration is sometimes mandatory for the final diagnosis, especially in unstable 
patients or in cases with a history of aortic grafting and gastrointestinal bleeding, where a 
GEF is suspected. Unfortunately only 50% of GEFs can be diagnosed by CT or MRI 
modalities. Operative exploration, graft excision and broth culture of the graft can lead to 
isolation of the responsible microorganisms and selection of proper antibiotic treatment. 
8. Prevention 
Prevention of graft contamination perioperatively is of great importance, given the high 
mortality and morbidity that follows a vascular infection. Antimicrobial prophylaxis should 
be administered within 60 min before incision and discontinued within 24 h after surgery. 
According to the published consensus of the Surgical Infection Prevention Guideline Writers 
Workgroup (SIPGWW), the recommended prophylactic antibiotics for cardiothoracic and 
vascular surgery include cefazolin and cefuroxime. [23] For intra-abdominal surgery 
coverage for anaerobes may be added (metronidazole). [24] 
Culture-specific antibiotics should be administered to patients who have coexisting 
infections. 
There are some principles that should be followed perioperatively, in order to prevent an 
infection:  
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 Patients should scrub the night before the operation 
 Hair of the operative site should be removed by clippers and not by razors so as to 
prevent skin trauma 
 Preoperative hospital stay should be minimized, if possible 
 Remote infections must be controlled before elective grafting interventions 
 Concomitant gastrointestinal procedures should be avoided, if a graft is planned to be 
used (cholecystectomy for asymptomatic cholelithiasis is possibly excepted) 
 The use of iodine-impregnated plastic drapes is recommended, so as to prevent graft 
contamination 
 Meticulous sterile technique is vital 
 Careful hemostasis and closure of surgical incisions in multiple layers are 
recommended 
 Irrigation of groin wounds with topical antibiotics before closure may decrease 
infection rates. [25] 
9. Therapeutic management of vascular infection 
9.1. General principles 
Presentation of vascular infections varies and there is, usually, no standard treatment. 
Treatment should be individualized according to infection site, clinical presentation and the 
isolated microorganisms. For the extracavitary graft infections there are some 
recommendations, based on infection grade, simplifying the complexity of treatment. (Table 
2) The main goal is eradication of the infection while preserving blood flow to the target 
organs or limbs. 
Preparation of the patient is important, though takes time. In unstable patients due to septic 
or hypovolemic shock, no delay is justified. Blood or fluid resuscitation, antibiotic coverage 
and urgent surgical treatment are the only option. For the rest of the cases, where time is 
available, patient’s cardiac, pulmonary and renal function should be optimized. Diabetic 
patients must have their glucose levels controlled. Malnourished patients can improve by 
enteral or parenteral nutrition. When an abdominal operation is planned, colon should be 
mechanically, cleansed. A Duplex scan of the lower limb veins is recommended, especially 
in cases of in situ replacement with autologous graft. Preoperative antibiotic coverage of the 
patient is crucial. 
Available options include graft excision with or without revascularization and graft 
preservation with local treatment. Graft excision can be followed by extra anatomic 
revascularization or in situ replacement of the graft.  
9.2. Preservation of the graft 
Preservation of the infected graft is indicated in few, selected cases, usually when infection 
involves autologous vein grafts or patches. [26-28] Patients must have no signs of sepsis and 
the graft should be patent with segmental contamination. Anastomoses must be spared.  
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and urgent surgical treatment are the only option. For the rest of the cases, where time is 
available, patient’s cardiac, pulmonary and renal function should be optimized. Diabetic 
patients must have their glucose levels controlled. Malnourished patients can improve by 
enteral or parenteral nutrition. When an abdominal operation is planned, colon should be 
mechanically, cleansed. A Duplex scan of the lower limb veins is recommended, especially 
in cases of in situ replacement with autologous graft. Preoperative antibiotic coverage of the 
patient is crucial. 
Available options include graft excision with or without revascularization and graft 
preservation with local treatment. Graft excision can be followed by extra anatomic 
revascularization or in situ replacement of the graft.  
9.2. Preservation of the graft 
Preservation of the infected graft is indicated in few, selected cases, usually when infection 
involves autologous vein grafts or patches. [26-28] Patients must have no signs of sepsis and 
the graft should be patent with segmental contamination. Anastomoses must be spared.  
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Outcome is better with vein or PTFE than polyester grafts, with early than late infections (˂4 
months) and with extracavitary grafts. Infections caused by single Gram positive and not 
multiple Gram negative organisms (e.g. Pseudomonas) may be considered for graft 
preservation and local treatment.  
Local treatment includes staged surgical debridement of infected tissues in healthy plane, 
mechanical irrigation of the wound (using povidone iodine solution and peroxide), on a 
regular basis, rotational muscle flap coverage, temporary use of antibiotic impregnated 
beads and VAC devices (vacuum assisted closure devices for wounds). Intravenous culture-
based antibiotics are essential. Persistent infection or sepsis is an indication of treatment 
failure which happens in 30% of the patients. [27] In such cases, graft excision with or 
without revascularization should follow.  
9.3. Graft excision 
Graft excision without revascularization is rarely an option, mostly in patients where the 
indication for the initial procedure was claudication, or in cases where the infection has led 
to graft thrombosis but with no signs of critical ischemia. In patent infected grafts, the 
decision regarding the need for immediate revascularization is based on temporary graft 
occlusion. The presence of Doppler pedal pulsatile signal and systolic ankle pressure greater 
than 40 mmHg is a sign of sufficient preexisting collaterals. In cases of infected bypass grafts 
with end to side anastomosis, the graft can be removed and an autologous patch can be 
placed at the site of proximal anastomosis. 
In the majority of the cases, graft excision should be accompanied by revascularization of 
the target organs or limbs, usually by means of extra-anatomic PTFE bypass, through 
uninfected tissues.  
This technique is suitable, mainly for aortoiliac or aortobifemoral infected grafts, for patients 
with GEE/GEF or for more diffuse infections with signs of systemic sepsis. Graft excision 
can be accomplished through celiotomy or left-side retroperitoneal incision, so as to avoid 
contaminated areas. Preoperative stenting of the ureters is recommended in cases of 
extensive infection, for protection during dissection and easier identification. Supraceliac 
aortic clamping and control of iliac arteries (at healthy segments, distally to the infected part 
of the graft) may be necessary, though sometimes difficult due to perigraft inflammation. 
Some centers advocate the use of intraluminal occlusion balloons. Meticulous dissection of 
the adherent viscera’s or duodenum, especially in patients with GEE/GEF is important. 
Necrotic bowel segments must be excised and bowel continuity should be restored by end 
to end anastomosis. Complete removal and culture of the aortoiliofemoral graft must follow. 
Extensive debridement and irrigation (by use of cytotoxic agents) of perigraft contaminated 
or necrotic tissues are essential. Closure of the aortic stump is performed by double layers of 
interrupted monofilament sutures. Prosthetic pledgets should be avoided. Coverage of the 
aortic stump with omentum pedicles is believed to prevent stump blowout and its 
catastrophic consequences. The same technique can be applied for the ligation of iliac 
arteries, but flow must be maintained at least to one hypogastric artery, in order to avoid 
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pelvic or colon ischemia. Placement of closed suction drains can be placed in the 
retroperitoneal space. Reported mortality rates range between 11-22%, while limb loss 10-
11%. [20,29] Stump blowout, which is a major complication, can happen up to 22% of the 
cases. [7] 
Several authors suggest that staged management of infected aortic grafts, show lower 
morbidity and mortality rates. [29,30] Hemodynamically unstable patients, are an exception, 
and the vascular surgeon should focus on the site of hemorrhage (septic hemorrhage from 
anastomosis, GEE/GEF). In the rest of the cases, it is recommended, to perform the extra-
anatomic bypass first, and graft excision can follow 1 to 2 days later. 
Aortobifemoral graft infections, especially in the groins, constitute a challenge for the 
surgeon. Unilateral ex situ bypass to the profunda femoris or superficial femoral artery 
through uninfected planes is an option, while bypass to the popliteal artery results in low 
rates of patency (58% in 6 months). [31] In bilateral groin infections, graft excision followed 
by unilateral axillofemoral bypass and autogenous vein cross-femoral bypass is another 
solution. 
In-situ graft replacement is an alternative solution, in selected cases. There should be no 
systemic signs of sepsis, any anastomotic bleeding or perigraft incorporation. Perigraft fluid 
cultures must be sterile unless bacteria of low virulence, such as S. Epidermis, are isolated. 
In fact, in patients with infection that involves the thoracic aorta or the visceral segment of 
abdominal aorta, in situ replacement may be the only option available. The most common 
grafts used in this technique are autologous grafts (e.g. superficial or deep veins of the 
limbs), antibiotic bonded prosthetic grafts or cryopreserved arterial allografts. (Figure 1.) 
Great saphenous vein (GSV) or superficial veins from the upper limb can be used in cases 
where infection affects infrainguinal, upper extremity, visceral or cerebrovascular 
procedures. A preoperative Duplex vein mapping is essential for estimation of vein’s 
condition and diameter. 
However, use of GSV in ilio-femoral or aorto-iliac reconstructions, results in low patency 
rates, due to diameter mismatch. [32] In these cases, superficial femoral vein harvesting has 
a strong indication. [33,34] Preoperative vein mapping is important. In cases of aortic 
reconstruction, with larger aortic diameter, “pantaloon technique” can be applied. (Figure 
1.) Compared to graft excision and extra anatomic bypass, in situ graft replacement presents 
better patency and recurrent infection rates. [35] Superficial femoral vein can be used also, in 
aortofemoral graft infections localized in the groin caused by S. epidermidis. However its use 
in secondary GEE/GEF is not recommended. Deep veins are used non reversed, after valve 
excision. 
Antibiotic bonded prosthetic grafts (PTFE or Dacron), can be used in segmental graft 
infections, where the isolated microorganism is of low virulence (e.g. S. Epidermidis) and 
the anastomoses are spared. [20] For example in segmental aortofemoral graft infections, 
with groin complications, especially in elderly patients, antibiotic bonded prosthetic grafts 
should be considered for replacement of one limb of the pre-existing graft. 
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Outcome is better with vein or PTFE than polyester grafts, with early than late infections (˂4 
months) and with extracavitary grafts. Infections caused by single Gram positive and not 
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pelvic or colon ischemia. Placement of closed suction drains can be placed in the 
retroperitoneal space. Reported mortality rates range between 11-22%, while limb loss 10-
11%. [20,29] Stump blowout, which is a major complication, can happen up to 22% of the 
cases. [7] 
Several authors suggest that staged management of infected aortic grafts, show lower 
morbidity and mortality rates. [29,30] Hemodynamically unstable patients, are an exception, 
and the vascular surgeon should focus on the site of hemorrhage (septic hemorrhage from 
anastomosis, GEE/GEF). In the rest of the cases, it is recommended, to perform the extra-
anatomic bypass first, and graft excision can follow 1 to 2 days later. 
Aortobifemoral graft infections, especially in the groins, constitute a challenge for the 
surgeon. Unilateral ex situ bypass to the profunda femoris or superficial femoral artery 
through uninfected planes is an option, while bypass to the popliteal artery results in low 
rates of patency (58% in 6 months). [31] In bilateral groin infections, graft excision followed 
by unilateral axillofemoral bypass and autogenous vein cross-femoral bypass is another 
solution. 
In-situ graft replacement is an alternative solution, in selected cases. There should be no 
systemic signs of sepsis, any anastomotic bleeding or perigraft incorporation. Perigraft fluid 
cultures must be sterile unless bacteria of low virulence, such as S. Epidermis, are isolated. 
In fact, in patients with infection that involves the thoracic aorta or the visceral segment of 
abdominal aorta, in situ replacement may be the only option available. The most common 
grafts used in this technique are autologous grafts (e.g. superficial or deep veins of the 
limbs), antibiotic bonded prosthetic grafts or cryopreserved arterial allografts. (Figure 1.) 
Great saphenous vein (GSV) or superficial veins from the upper limb can be used in cases 
where infection affects infrainguinal, upper extremity, visceral or cerebrovascular 
procedures. A preoperative Duplex vein mapping is essential for estimation of vein’s 
condition and diameter. 
However, use of GSV in ilio-femoral or aorto-iliac reconstructions, results in low patency 
rates, due to diameter mismatch. [32] In these cases, superficial femoral vein harvesting has 
a strong indication. [33,34] Preoperative vein mapping is important. In cases of aortic 
reconstruction, with larger aortic diameter, “pantaloon technique” can be applied. (Figure 
1.) Compared to graft excision and extra anatomic bypass, in situ graft replacement presents 
better patency and recurrent infection rates. [35] Superficial femoral vein can be used also, in 
aortofemoral graft infections localized in the groin caused by S. epidermidis. However its use 
in secondary GEE/GEF is not recommended. Deep veins are used non reversed, after valve 
excision. 
Antibiotic bonded prosthetic grafts (PTFE or Dacron), can be used in segmental graft 
infections, where the isolated microorganism is of low virulence (e.g. S. Epidermidis) and 
the anastomoses are spared. [20] For example in segmental aortofemoral graft infections, 
with groin complications, especially in elderly patients, antibiotic bonded prosthetic grafts 
should be considered for replacement of one limb of the pre-existing graft. 
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Figure 1. In situ aortic reconstruction after graft infection (A= infected bifurcated graft, B= autologous 
replacement (“Pantaloon” technique),  C= heterologous replacement (bovine aorta),D= Repair with 
silver-bonded synthetic graft) 
An alternative option, especially in more diffuse infections, is the use of cryopreserved 
arterial allografts. While the survival and recurrent infection rates are comparable to other 
grafts, increased dilation (17%) and stenosis (20%) rates were noticed. [36] 
Overall, outcomes following deep venous replacement are better than with the use of 
arterial allografts or implantation of a “new” prosthetic graft. When applied to low-grade 
aortic graft infections without GEE or GEF, this procedure is safe (4% in-hospital mortality), 
with a low (3%) incidence of long-term limb loss. In cases with GEE/GEF, mortality can 
reach 20%, similar to graft excision and ex-situ bypass. 
10. Adjunctive treatments 
10.1. Antibiotic-loaded beads 
In vascular infections, where graft preservation and serial debridement of the wound is the 
selected treatment, implantation of antibiotic –loaded beads is an alternative adjunctive 
therapy. They are mainly used in extracavitary graft infections. Beads are usually loaded 
with vancomycin, daptomycin, tobramycin, or gentamicin based on initial culture results. 
Initial results are encouraging, with wound healing in 90% of the cases. [37] 
10.2. Muscle flap coverage  
Infected grafts that are treated locally must be surrounded by healthy, non contaminated 
tissues. Coverage of the graft with a well vascularised, not infected muscle flap, contributes 
to wound healing. Sartorius muscle flap coverage is the most common technique used in 
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graft infections located in the groins. [38] This technique is mainly indicated, as an adjunct 
of graft preservation or in situ replacement therapies, especially in cases of recurrent 
infections or extensive tissue deficit after debridement. The muscle is divided from its 
proximal attachment to the iliac crest and sutured medially, so as to cover the infected graft. 
In a published series, recurrent infection rate after use of Sartorius flap was only 7%. [39] 
Another similar technique is the rotational use of flaps of muscles that are mobilized from a 
separate healthy site. Their blood supply doesn’t come from the infected area. The gracilis 
rectus abdominis, tensor fasciae latae or rectus femoris can be used, depending on site of 
infection. [40] Some authors consider this technique as a better option than the use of 
Sartorius muscle. [38] 
10.3. Antibiotics 
When the diagnosis of vascular infection is made, parenteral broad spectrum antibiotics 
should be given, until isolation of the infecting micro-organism is accomplished, through 
cultures. Additionally, if cultures reveal no pathogen or there are no available specimens for 
culture, empiric antimicrobial treatment should target skin-colonizing organisms and 
nosocomial pathogens as well. 
Vancomycin is an indispensable agent in the initial empiric antimicrobial regimen, because 
of its excellent anti-Gram-positive spectrum. Teicoplanin has a similar antimicrobial 
spectrum to vancomycin but has not been tested in large prospective series for the treatment 
of vascular infections. [41-44] 
Alternative antimicrobial agents are linezolid and quinupristin/dalfopristin, which provide 
coverage for methicillin-resistant staphylococci (MRSA and MRSE) and vancomycin-
resistant enterococci (VRE). Their use should be reserved for infections due to pathogens 
resistant to vancomycin, or in patients who are allergic to vancomycin. [45,46] 
Once cultures reveal the infecting pathogen , parenteral antibiotic treatment should be 
initiated, without any delay. 
The duration of therapy is individualized but most authors recommend 4–6 weeks of 
treatment after the removal of the infected graft. 
11. Management of specific graft site infection 
11.1. Carotid infection  
Depending on grading, carotid artery infections are reported up to 2% of cases. [47] Szylagyi 
III infections are found in a rate of less than 1%. [48,49] The majority of infections are 
postoperative wound contaminations, which seldom extent to the suture line. Wound 
dehiscence with septic haemorrhage is extremely rarely observed. There are reports that the 
use of prosthetic materials increases the infection rate. However, the management of such 
infections that may lead to catastrophic life-threatening septic complications is especially 
challenging. The standard treatment includes wound debridement and prosthetic graft 
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with a low (3%) incidence of long-term limb loss. In cases with GEE/GEF, mortality can 
reach 20%, similar to graft excision and ex-situ bypass. 
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In vascular infections, where graft preservation and serial debridement of the wound is the 
selected treatment, implantation of antibiotic –loaded beads is an alternative adjunctive 
therapy. They are mainly used in extracavitary graft infections. Beads are usually loaded 
with vancomycin, daptomycin, tobramycin, or gentamicin based on initial culture results. 
Initial results are encouraging, with wound healing in 90% of the cases. [37] 
10.2. Muscle flap coverage  
Infected grafts that are treated locally must be surrounded by healthy, non contaminated 
tissues. Coverage of the graft with a well vascularised, not infected muscle flap, contributes 
to wound healing. Sartorius muscle flap coverage is the most common technique used in 
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graft infections located in the groins. [38] This technique is mainly indicated, as an adjunct 
of graft preservation or in situ replacement therapies, especially in cases of recurrent 
infections or extensive tissue deficit after debridement. The muscle is divided from its 
proximal attachment to the iliac crest and sutured medially, so as to cover the infected graft. 
In a published series, recurrent infection rate after use of Sartorius flap was only 7%. [39] 
Another similar technique is the rotational use of flaps of muscles that are mobilized from a 
separate healthy site. Their blood supply doesn’t come from the infected area. The gracilis 
rectus abdominis, tensor fasciae latae or rectus femoris can be used, depending on site of 
infection. [40] Some authors consider this technique as a better option than the use of 
Sartorius muscle. [38] 
10.3. Antibiotics 
When the diagnosis of vascular infection is made, parenteral broad spectrum antibiotics 
should be given, until isolation of the infecting micro-organism is accomplished, through 
cultures. Additionally, if cultures reveal no pathogen or there are no available specimens for 
culture, empiric antimicrobial treatment should target skin-colonizing organisms and 
nosocomial pathogens as well. 
Vancomycin is an indispensable agent in the initial empiric antimicrobial regimen, because 
of its excellent anti-Gram-positive spectrum. Teicoplanin has a similar antimicrobial 
spectrum to vancomycin but has not been tested in large prospective series for the treatment 
of vascular infections. [41-44] 
Alternative antimicrobial agents are linezolid and quinupristin/dalfopristin, which provide 
coverage for methicillin-resistant staphylococci (MRSA and MRSE) and vancomycin-
resistant enterococci (VRE). Their use should be reserved for infections due to pathogens 
resistant to vancomycin, or in patients who are allergic to vancomycin. [45,46] 
Once cultures reveal the infecting pathogen , parenteral antibiotic treatment should be 
initiated, without any delay. 
The duration of therapy is individualized but most authors recommend 4–6 weeks of 
treatment after the removal of the infected graft. 
11. Management of specific graft site infection 
11.1. Carotid infection  
Depending on grading, carotid artery infections are reported up to 2% of cases. [47] Szylagyi 
III infections are found in a rate of less than 1%. [48,49] The majority of infections are 
postoperative wound contaminations, which seldom extent to the suture line. Wound 
dehiscence with septic haemorrhage is extremely rarely observed. There are reports that the 
use of prosthetic materials increases the infection rate. However, the management of such 
infections that may lead to catastrophic life-threatening septic complications is especially 
challenging. The standard treatment includes wound debridement and prosthetic graft 
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replacement with autologous material (e.g. saphenous vein). Recently the use of 
sternocleidomastoid muscle flap plasty for coverage of the infected area was described. 
More recently, carotid stent infections were reported in up to 0,4 % of cases. [48] This 
complication may present primary or secondary to neck irradiation and trauma. [48,50,51] 
The treatment principles are similar to post-CEA infections. The use of vacuum assisted 
closure device emerges as a new trend with promising results. [52]  
11.2. Infection of vascular access 
Vascular access Infection is a major complication for haemodialysis patients. Clinical 
symptoms vary from simple local inflammation to systemic sepsis. In some cases, septic 
haemorrhage may develop, which is a life-threatening condition. (Figure 2.) Reported risk 
factors for this adverse event include immunodeficiency, low serum albumin level, female 
gender, adult polycystic kidney disease, diabetes mellitus, inadequate dialysis and the use 
of catheters or synthetic graft. [53] It is estimated that 30 to 50% of bacteraemia in 
haemodialysis patients is caused by vascular access infection. [53] There are reports that 
infection rates range from 0.5 to 3.5% for autogenous AVF, 5-8% for prosthetic graft accesses 
and 2-5.5 episodes of bacteremia per 1000 patient days for central venous catheters. [54,55] 
 
Figure 2. Infection of brachio-cephalic fistula (Cimino) at the wrist with septic bleeding 
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Early postoperative graft infections usually affect the whole graft. The treatment of choice is 
excision of the entire graft. Late localised infection at the needles sites can be managed by 
segmental graft removal and bypass through uninfected planes. Sometimes, though, total 
excision is necessary. 
The use of V.A.C. as an adjunctive treatment may be beneficial. Autogenous AV access 
infections often can be effectively treated with systemic antibiotics. In case of infected 
pseudoaneurysms or abscesses access ligation of the access or segmental bypass are 
mandatory. 
Catheter infection presentation varies. Exit-site infections are treated with local antibiotics. 
In case of failure, parenteral antibiotics should be administered. Tunnel tract infections 
require intravenous antibiotics, and catheter exchange through a new tunnel and exit site. 
These patients require at least 3 weeks of culture-based antibiotic therapy and monitoring 
for recurrent infection. [56] Patients with systemic sepsis should have their catheter removed 
and a temporary catheter inserted. A new cuffed catheter may be placed if the patient 
remains afebrile for at least 48-72 hours. 
11.3. Infection of thoracic aorta 
The incidence of infections affecting thoracic or thoracoabdominal aortic grafts, ranges from 
0.5% to 1.9%. Complications can be fatal, and mortality is high. Open surgical repair for 
primary or secondary thoracic aorta infections are associated with significant mortality and 
morbidity. Graft excision and extra-anatomic bypass are usually not applicable to infections 
involving ascending, transverse arch or descending aorta grafts. For most of these cases, in-
situ replacement with the use of prosthetic grafts is the treatment of choice. The use of 
silver-bonded or antimicrobial-bonded synthetic grafts is possibly preferable. Surgical 
debridement and antibacterial irrigation of infected tissues are important. It is reported that 
coverage of the graft with pericardial fat, rotated muscles (e.g. pectoralis major, latissimus 
dorsi, rectus abdominis) or with a pedicle of greater omentum can prevent recurrent 
infections. [57] Antibiotic coverage is necessary. Mortality is reported to be 10-20% while 
reinfection rates 20%. [57,58] The only extra-anatomic repair, that may be recommended, is 
prosthetic grafting from the ascending to abdominal aorta, tunnelling through the 
diaphragm, with subsequent infected graft excision through a left thoracotomy. 
Limited surgical strategy involving extensive mediastinal debridement is reported in cases 
where infection is associated with sternal wound infection by low virulent pathogens. [59] 
Endovascular stent graft repair has been reported as an attractive and effective treatment 
option, but the persistence of infection is always a concern. Though in cases of severe local 
inflammation, with or without haemorrhage, this technique can serve as bridging therapy. [60] 
Stent or stent-graft infections in the thoracic aorta are extremely rare. They are usually met 
in the literature as complications of systemic specific infections such as TBC or brucellosis. 
The general principles of treatment are similar to the thoracic graft infection. Some papers 
report secondary stent-graft infections after TEVAR due to aorto-oesophageal or aorto-
bronchial fistulas. 
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for recurrent infection. [56] Patients with systemic sepsis should have their catheter removed 
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0.5% to 1.9%. Complications can be fatal, and mortality is high. Open surgical repair for 
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morbidity. Graft excision and extra-anatomic bypass are usually not applicable to infections 
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silver-bonded or antimicrobial-bonded synthetic grafts is possibly preferable. Surgical 
debridement and antibacterial irrigation of infected tissues are important. It is reported that 
coverage of the graft with pericardial fat, rotated muscles (e.g. pectoralis major, latissimus 
dorsi, rectus abdominis) or with a pedicle of greater omentum can prevent recurrent 
infections. [57] Antibiotic coverage is necessary. Mortality is reported to be 10-20% while 
reinfection rates 20%. [57,58] The only extra-anatomic repair, that may be recommended, is 
prosthetic grafting from the ascending to abdominal aorta, tunnelling through the 
diaphragm, with subsequent infected graft excision through a left thoracotomy. 
Limited surgical strategy involving extensive mediastinal debridement is reported in cases 
where infection is associated with sternal wound infection by low virulent pathogens. [59] 
Endovascular stent graft repair has been reported as an attractive and effective treatment 
option, but the persistence of infection is always a concern. Though in cases of severe local 
inflammation, with or without haemorrhage, this technique can serve as bridging therapy. [60] 
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11.4. Vascular infections in the groin  
Infections after vascular reconstructions are most common in the groins. The main 
predisposing factors are surgical division of lymphatic channels, infected lymph glands, the 
superficial location of vascular grafts and the proximity of the surgical site to the perineum. 
A number of serious complications can arise such as fistula, septic hemorrhage, septic 
embolism and limb threatening ischemia. [61,62] Imaging of the infected area is essential for 
the diagnosis. (Figure 3.)  
 
Figure 3. CT findings in a patient with Szilagyi III infection in the groin. (1=fistula, 2=perigraft 
inflammation/secretion, 3=graft) 
There is a lot of controversy about the treatment of choice in groin infections, following 
vascular graft placement. It depends on the degree of graft involvement. If there is no graft 
infection (Szilagyi grade I or II), then wound debridement or drainage with culture-directed 
antibiotic administration is considered to be adequate. If, graft contamination is present 
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(Szilagyi grade III), then further treatment is controversial. In the majority of the cases, 
treatment includes excision of the graft, surgical debridement of the infected tissues 
followed by restoration of blood flow by in situ or extra-anatomic reconstruction.[63,64] 
Obturator or lateral femoral bypass are the most frequent extra-anatomic procedures for 
limb revascularization in vascular groin infections. [65-67]  An 80% cumulative patency rate 
at 6 years has been reported. [68]   However, many concerns have been associated to extra-
anatomic bypass including lengthy procedure time, difficulty of extra-anatomic routing, 
high amputation rates. [69]. When in-situ reconstruction is selected, cryopreserved aortic 
homograft, autologous deep femoral vein, or rifampin-bonded prostheses can serve as 
grafts. Disadvantages associated with in situ reconstructions, include lengthier operative 
time in case of vein harvesting and contraindication in patients with previous deep vein 
thrombosis, high complication rates of cryopreserved allografts and lack of availability in 
emergent cases. In situ reconstructions are associated with higher stress than extra-anatomic 
bypasses, which is important in high risk patients. 
Graft preservation is considered an option when the graft is patent, the entire length of the 
graft is not involved by the infection, the anastomosis is intact, there are no systemic signs of 
sepsis and the contaminating organism is not a virulent strain of bacteria, especially MRSA 
and Pseudomonas aeruginosa . [70,71] 
The use of local muscle flaps to promote wound healing and vascular graft salvage has been 
well documented. [72-74]  
VAC therapy has been reported as an adjunctive or definitive treatment for groin infections 
involving exposed grafts especially in high-risk surgical patients who are not candidates for 
graft replacement. VAC therapy along with aggressive debridement, antibiotic therapy and 
muscle flap coverage may be an effective alternative to current management strategies. 
Some authors recommend the use of V.A.C. even after graft replacement, in treatment of 
Szilagyi III infections. (Figure 4.) 
The majority of current clinical evidence supporting the use of negative pressure therapy 
(VAC) on infected groin wounds following vascular reconstructions has been based on 
clinical experience and small cohort studies. However graft/patch salvage rates up to 97.2%, 
have been reported. [75]. 
11.5. Infection of femoral, popliteal, tibial grafts 
Infection of infrainguinal grafts is quite rare but it can present with anastomotic disruption 
and septic hemorrhage or emboli. The preferred method of treatment is usually graft 
excision and revascularization with bypass grafting via adjacent or remote tunneling. In-situ 
revascularization is feasible in 80% of the cases. The use of autogenous vein grafts is 
preferred when they are available. Some authors advocate staged treatment. In this case, 
closure of the arteriotomies with monofilament suture and the administration of systemic 
and topical antibiotics follow the removal of the graft. Patients who had prosthetic grafts 
inserted for claudication or patients who do not develop limb-threatening ischemia after 
graft excision may not need revascularization.  
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homograft, autologous deep femoral vein, or rifampin-bonded prostheses can serve as 
grafts. Disadvantages associated with in situ reconstructions, include lengthier operative 
time in case of vein harvesting and contraindication in patients with previous deep vein 
thrombosis, high complication rates of cryopreserved allografts and lack of availability in 
emergent cases. In situ reconstructions are associated with higher stress than extra-anatomic 
bypasses, which is important in high risk patients. 
Graft preservation is considered an option when the graft is patent, the entire length of the 
graft is not involved by the infection, the anastomosis is intact, there are no systemic signs of 
sepsis and the contaminating organism is not a virulent strain of bacteria, especially MRSA 
and Pseudomonas aeruginosa . [70,71] 
The use of local muscle flaps to promote wound healing and vascular graft salvage has been 
well documented. [72-74]  
VAC therapy has been reported as an adjunctive or definitive treatment for groin infections 
involving exposed grafts especially in high-risk surgical patients who are not candidates for 
graft replacement. VAC therapy along with aggressive debridement, antibiotic therapy and 
muscle flap coverage may be an effective alternative to current management strategies. 
Some authors recommend the use of V.A.C. even after graft replacement, in treatment of 
Szilagyi III infections. (Figure 4.) 
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(VAC) on infected groin wounds following vascular reconstructions has been based on 
clinical experience and small cohort studies. However graft/patch salvage rates up to 97.2%, 
have been reported. [75]. 
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Infection of infrainguinal grafts is quite rare but it can present with anastomotic disruption 
and septic hemorrhage or emboli. The preferred method of treatment is usually graft 
excision and revascularization with bypass grafting via adjacent or remote tunneling. In-situ 
revascularization is feasible in 80% of the cases. The use of autogenous vein grafts is 
preferred when they are available. Some authors advocate staged treatment. In this case, 
closure of the arteriotomies with monofilament suture and the administration of systemic 
and topical antibiotics follow the removal of the graft. Patients who had prosthetic grafts 
inserted for claudication or patients who do not develop limb-threatening ischemia after 
graft excision may not need revascularization.  
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Figure 4. Application of vacuum-assisted closure technique (VAC technique) in a patient with graft 
infection in groin (A=Szilagyi III infection with cutaneous fistula, B=marking of infected area with use of 
methylene blue, C=Wound debridement and replacement of infected graft with a silver-bonded 
synthetic graft, D=preparation of sartorius muscle, E= coverage of the graft with the muscle flap, 
D=Application of VAC system 
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Graft preservation is reported as an alternative option, especially in high risk patients, 
unless there is sepsis or anastomotic bleeding. In such cases local treatment with surgical 
debridement, antibiotic administration and muscle flap coverage is applied. [19,30] 
Treatment of peripheral grafts infection shows low mortality rates ( 0-9%) but increased 
amputation rates (33-67%) compared to treatment of aortic grafts infection. [11,76] 
11.6. Endovascular stent-graft and stent infections 
Infections involving endoluminal devices (stents or stent-grafts) are rare, although they 
present with increased frequency. The reported incidence after AAA repair is 0.2% to 1.2%. 
Infection of peripheral bare stents are extremely rare (<0.1%). They present clinically with 
sepsis, septic emboli, mycotic aneurysm or GEE/GEF. Periprocedural bacteremia from 
remote sites of infection or during secondary endovascular interventions is considered to be 
the cause of stent-graft contamination. [77] Perigraft inflammation or fluid is the main CT 
findings with diagnostic sensitivity of 85%. Treatment consists of antibiotics and graft 
excision followed by extra-anatomic bypass or in situ autogenous replacement. Mortality is 
high and ranges between 20-30%. [78,79]  Endovascular treatment should be considered 
only as a bridging therapy. [80,81] 
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1. Introduction 
Peripheral arterial occlusive disease (PAOD) commonly results from progressive narrowing 
or occlusion of arteries in the lower extremities mostly due to atherosclerosis. The 
atherosclerotic process of progressive narrowing and hardening of arteries can occur in each 
artery in the human body, however it mainly affects coronary, cerebral and peripheral 
arteries especially those in the lower extremities(1). The preferential sites of involvement of 
PAOD are the femoral and popliteal arteries in 80-90%, the tibial and peroneal arteries in 40-
50% and in 30% the aorta and iliac arteries(2). The manifestation of PAOD ranges from no 
symptoms to tissue loss that may eventually requires amputation of an affected limb. The 
majority of patients with PAOD have asymptomatic or atypical disease (figure 1).  
Total disease prevalence based on objective testing has been evaluated in several 
epidemiologic studies and ranges from 3% to 10% in adults, increasing to 15 to 20% in 
persons over 70 years. PAOD increases progressively with age, beginning after the age of 
40(3). The relationship between PAOD prevalence and age was illustrated on data from the 
1999–2000 National Health and Nutrition Examination Survey (NHANES), an ongoing cross-
sectional survey of the civilian, non-institutionalized population of the United States. The 
prevalence of PAOD, defined as an ankle-brachial index (ABI) <0.90 in either leg, was 0.9% 
between the ages of 40-49, 2.5% between the ages of 50-59, 4.7% between the ages of 60-69, 
and 14.5% in ages 70 and older(3). These numbers indicate that PAOD affects more than 5 
million adults in the United States, while international guidelines reveal some 27 million 
affected individuals in North America and Europe(1). The PARTNERS study (PAOD 
Awareness, Risk, and Treatment: New Resources for Survival) screened 6979 subjects for 
PAOD using the ABI (with PAOD defined as an ABI of ≤0.90 or a prior history of lower 
extremity revascularization)(4). Subjects were evaluated in primary care practices in the 
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United States if they were above 70 years of age or between 50–69 years when presenting 
with a risk factor for vascular disease (smoking, diabetes). PAOD was detected in 1865 
patients (29% of the cohort). Classic claudication or symptomatic PAOD was present in only 
5.5% of the newly diagnosed patients with PAOD. Some 12.6% of the patients with a prior 
diagnosis of PAOD had claudication. Other studies have evaluated symptomatic and 
asymptomatic PAOD patients in the same population. The ratio of the two is independent of 
age and is usually in the range of 1:3 to 1:4(1). It may be concluded that PAOD is still growing 
as a clinical problem due to the increasingly aged population in developed countries.  
 
Legend to figure: PAD – peripheral arterial disease; CLI – critical limb ischemia; CV – cardiovascular; MI – myocardial 
infarction.  
Figure 1. 5 years disease prognosis in claudicants (adapted from TASC II guidelines (1)). 
2. Etiology of symptomatic PAOD (Intermittent Claudication) 
50 – 80 % of PAOD patients are symptomatic and because of their complaints most of them 
will present themselves at a patient outdoor clinic. Symptomatic PAOD patients will have in 
20-50% of the cases symptoms of typical intermittent claudication (IC, which means ‘to 
limp’) (figure 1). IC is defined as muscle discomfort in the lower limb reproducibly elicited 
by exercise and relieved by rest within 10 minutes(1).  
Patients with IC have sufficient blood flow at rest and, therefore do not experience limb 
symptoms at rest. With exercise, occlusive or narrowing lesions in the arterial supply of the 
leg muscles limit the increase in blood flow resulting in a mismatch of oxygen supply and 
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muscle metabolic demand that is associated with the symptom of claudication. This 
mismatch causes cramping or aching pain in the buttock, hip, thigh, calf or in rare occasions 
the foot, forcing the patient to pause. In rest, the oxygen debt can be redeemed and 
symptoms are relieved. In women, the incidence rates of IC are approximately 50% lower 
than in men(5). IC has an approximately 3% prevalence in the general population in patients 
aged 40 up to 6% in patients aged 60 years and increasing in older age(1).  
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Adventitial cystic disease 
Table 1. Etiology of lower extremity ischemia 
Nerve root compression 
Spinal stenosis 
Hip / foot arthritis 
Arthritic, inflammatory processes 
Compartment syndrome 
Venous claudication 
Symptomatic Bakers cyste 
Table 2. Common differential diagnoses of non – vascular origin. 
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Eventually any process that results in arterial stenosis or occlusion can cause symptoms of 
claudication, ischemic pain, or tissue loss but the vast majority of patients with claudication 
suffer from atherosclerosis. Aetiologies of lower extremity ischemia due to arterial stenosis 
or occlusion other than atherosclerosis are shown in table 1.  
Arterial aneurysms can be the source of embolic debris leading to arterial obstruction 
resulting in symptoms of lower extremity ischemia. Popliteal entrapment syndrome can also 
present with IC and should be suspected in the young patient who presents with 
claudication but lacks atherosclerotic risk factors. In endurance athletes, especially cyclists, 
an even more unusual cause of claudication is due to repeated trauma (stretching or 
kinking) of the external iliac artery which can result in endofibrosis of the vessel(6).  
Other diseases of non-vascular origin should also be considered in the differential diagnosis 
of leg pain (table 2). These include neurological, musculoskeletal and venous disorders. 
Neurological pain (“spinal claudication”) is predominantly due to neurospinal (eg, disc 
disease, spinal stenosis, tumor) or neuropathic causes (eg, diabetes, alcohol abuse). 
Musculoskeletal pain derives from the bones, joints, ligaments, tendons, and fascial 
elements of the lower extremity. Clinical history taking and physical examination can help 
distinguish between some of the less common causes of these disorders, which is important 
to instate an effective treatment for a patient with IC complaints. 
3. Prognostics and mortality 
PAOD and IC are strong predictors for coinciding atherosclerotic disease and related 
mortality. The prevalence of cerebrovascular disease in patients with PAOD is about 25-
50%(7). The 10-year mortality rate due to cardiovascular disease is 62% for men with PAOD 
compared to 17% in the population of men without PAOD. For women with PAOD the 10-
year mortality rate is 33% compared to 12% without PAOD(8). In a subgroup of patients 
with severe and symptomatic PAOD a 15-fold increase in mortality rate was found(8).  
For IC, a 5-year mortality rate of 19.2 % is described, of which 70% is due to cardiovascular 
causes. Non-fatal cardiovascular events (e.g. myocardial infarction, stroke) in patients with 
IC are found in 29% at 5 years of follow-up(5). Compared to patients with IC, subjects with 
asymptomatic PAOD appear to have the same increased risk of cardiovascular events and 
death(5). Nonetheless, for those afflicted, IC impacts negatively on walking ability and 
health-related quality of life (QoL)(9, 10).  
4. General management of PAOD 
PAOD comes with serious health risks. An overall strategy and basic treatment is well 
described in several international guidelines like the American College of Cardiology/ 
American Heart Association (ACC/AHA) and Trans-Atlantic Inter-Society Consensus on 
Management of Peripheral Arterial Disease (TASC II)(1, 11). Treatment of PAOD should 
consist of a multicomponent therapy of cardiovascular risk reduction (1) including 
lifestyle coaching (2) and symptomatic treatment (3). The first two components aim to 
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prevent cardiovascular events (myocardial infarction, stroke) and related morbidity and 
mortality. The most important modifiable risk factors for atherosclerosis are smoking, 
hypertension, diabetes mellitus, hyperlipidemia and obesity(12). The third component is 
to improve QoL and realized with daily exercise supplemented with supervised exercise 
therapy (SET).  
5. Smoking cessation 
Smoking is a potent risk factor for symptomatic PAOD, with an important and consistent 
dose-response relationship(13). The prevalence of symptomatic PAOD was increased 2.3-fold 
in current smokers. Even in former smokers the prevalence was substantially increased by a 
factor of 2.6. Smoking cessation is associated with a decline in the incidence of IC. Results 
from the Edinburgh Artery Study found that the relative risk of IC was 3.7 in smokers 
compared with 3.0 in ex-smokers (who had discontinued smoking for less than 5 years)(1). In 
a meta-analysis of 12,603 smokers who had prior MI, CABG, angioplasty, or known coronary 
heart disease, the relative risk of mortality for quitters compared with those who continued to 
smoke was 0.64 (95% CI 0.58-0.71)(14). Observational studies have found that the risk of 
death, myocardial infarction and amputation is substantially greater, and lower extremity 
angioplasty and open surgical revascularization patency rates are lower in individuals with 
PAOD who continue to smoke than in those who stop smoking(15). Efforts to achieve 
smoking cessation are recommended for patients with lower extremity PAOD(13). A 
physician advice coupled with frequent follow-up achieves 1-year smoking cessation rates of 
approximately 5% compared with only 0.1% in individuals who try to quit smoking without 
a physician’s intervention(16). In patients with PAOD, comprehensive smoking cessation 
programs that included individualized counseling and pharmacological support significantly 
increased the rate of smoking cessation at 6 months compared with verbal advice to quit 
smoking (21.3% versus 6.8%, p<0.02)(17). Therefore the focused update of the guideline for 
the management of smoking patients recommended that current smokers or former smokers 
should be asked about their status of tobacco use at every visit (Level of Evidence: A). 
Furthermore patients should be assisted with counseling and developing a plan for quitting 
that may include pharmacotherapy and/or referral to a smoking cessation program(15). 
6. Hypertension 
Hypertension is a major risk factor for PAOD. However, data evaluating whether 
antihypertensive therapy alters the progression of claudication are lacking. Nevertheless, 
international guidelines support the treatment of hypertension in patients with PAOD to 
reduce morbidity from cardiovascular and cerebrovascular disease. In this high-risk group 
the current recommendation is a goal of 140/90 mmHg, or even 130/80 mmHg if the patient 
also has diabetes or renal insufficiency. In PAOD, thiazides and ACE inhibitors should be 
considered as initial blood-pressure lowering drugs to reduce the risk of cardiovascular 
events. Beta-adrenergic blocking drugs have been discouraged in PAOD because of the 
possibility of worsening claudication symptoms. In a Cochrane review there was no 
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Eventually any process that results in arterial stenosis or occlusion can cause symptoms of 
claudication, ischemic pain, or tissue loss but the vast majority of patients with claudication 
suffer from atherosclerosis. Aetiologies of lower extremity ischemia due to arterial stenosis 
or occlusion other than atherosclerosis are shown in table 1.  
Arterial aneurysms can be the source of embolic debris leading to arterial obstruction 
resulting in symptoms of lower extremity ischemia. Popliteal entrapment syndrome can also 
present with IC and should be suspected in the young patient who presents with 
claudication but lacks atherosclerotic risk factors. In endurance athletes, especially cyclists, 
an even more unusual cause of claudication is due to repeated trauma (stretching or 
kinking) of the external iliac artery which can result in endofibrosis of the vessel(6).  
Other diseases of non-vascular origin should also be considered in the differential diagnosis 
of leg pain (table 2). These include neurological, musculoskeletal and venous disorders. 
Neurological pain (“spinal claudication”) is predominantly due to neurospinal (eg, disc 
disease, spinal stenosis, tumor) or neuropathic causes (eg, diabetes, alcohol abuse). 
Musculoskeletal pain derives from the bones, joints, ligaments, tendons, and fascial 
elements of the lower extremity. Clinical history taking and physical examination can help 
distinguish between some of the less common causes of these disorders, which is important 
to instate an effective treatment for a patient with IC complaints. 
3. Prognostics and mortality 
PAOD and IC are strong predictors for coinciding atherosclerotic disease and related 
mortality. The prevalence of cerebrovascular disease in patients with PAOD is about 25-
50%(7). The 10-year mortality rate due to cardiovascular disease is 62% for men with PAOD 
compared to 17% in the population of men without PAOD. For women with PAOD the 10-
year mortality rate is 33% compared to 12% without PAOD(8). In a subgroup of patients 
with severe and symptomatic PAOD a 15-fold increase in mortality rate was found(8).  
For IC, a 5-year mortality rate of 19.2 % is described, of which 70% is due to cardiovascular 
causes. Non-fatal cardiovascular events (e.g. myocardial infarction, stroke) in patients with 
IC are found in 29% at 5 years of follow-up(5). Compared to patients with IC, subjects with 
asymptomatic PAOD appear to have the same increased risk of cardiovascular events and 
death(5). Nonetheless, for those afflicted, IC impacts negatively on walking ability and 
health-related quality of life (QoL)(9, 10).  
4. General management of PAOD 
PAOD comes with serious health risks. An overall strategy and basic treatment is well 
described in several international guidelines like the American College of Cardiology/ 
American Heart Association (ACC/AHA) and Trans-Atlantic Inter-Society Consensus on 
Management of Peripheral Arterial Disease (TASC II)(1, 11). Treatment of PAOD should 
consist of a multicomponent therapy of cardiovascular risk reduction (1) including 
lifestyle coaching (2) and symptomatic treatment (3). The first two components aim to 
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prevent cardiovascular events (myocardial infarction, stroke) and related morbidity and 
mortality. The most important modifiable risk factors for atherosclerosis are smoking, 
hypertension, diabetes mellitus, hyperlipidemia and obesity(12). The third component is 
to improve QoL and realized with daily exercise supplemented with supervised exercise 
therapy (SET).  
5. Smoking cessation 
Smoking is a potent risk factor for symptomatic PAOD, with an important and consistent 
dose-response relationship(13). The prevalence of symptomatic PAOD was increased 2.3-fold 
in current smokers. Even in former smokers the prevalence was substantially increased by a 
factor of 2.6. Smoking cessation is associated with a decline in the incidence of IC. Results 
from the Edinburgh Artery Study found that the relative risk of IC was 3.7 in smokers 
compared with 3.0 in ex-smokers (who had discontinued smoking for less than 5 years)(1). In 
a meta-analysis of 12,603 smokers who had prior MI, CABG, angioplasty, or known coronary 
heart disease, the relative risk of mortality for quitters compared with those who continued to 
smoke was 0.64 (95% CI 0.58-0.71)(14). Observational studies have found that the risk of 
death, myocardial infarction and amputation is substantially greater, and lower extremity 
angioplasty and open surgical revascularization patency rates are lower in individuals with 
PAOD who continue to smoke than in those who stop smoking(15). Efforts to achieve 
smoking cessation are recommended for patients with lower extremity PAOD(13). A 
physician advice coupled with frequent follow-up achieves 1-year smoking cessation rates of 
approximately 5% compared with only 0.1% in individuals who try to quit smoking without 
a physician’s intervention(16). In patients with PAOD, comprehensive smoking cessation 
programs that included individualized counseling and pharmacological support significantly 
increased the rate of smoking cessation at 6 months compared with verbal advice to quit 
smoking (21.3% versus 6.8%, p<0.02)(17). Therefore the focused update of the guideline for 
the management of smoking patients recommended that current smokers or former smokers 
should be asked about their status of tobacco use at every visit (Level of Evidence: A). 
Furthermore patients should be assisted with counseling and developing a plan for quitting 
that may include pharmacotherapy and/or referral to a smoking cessation program(15). 
6. Hypertension 
Hypertension is a major risk factor for PAOD. However, data evaluating whether 
antihypertensive therapy alters the progression of claudication are lacking. Nevertheless, 
international guidelines support the treatment of hypertension in patients with PAOD to 
reduce morbidity from cardiovascular and cerebrovascular disease. In this high-risk group 
the current recommendation is a goal of 140/90 mmHg, or even 130/80 mmHg if the patient 
also has diabetes or renal insufficiency. In PAOD, thiazides and ACE inhibitors should be 
considered as initial blood-pressure lowering drugs to reduce the risk of cardiovascular 
events. Beta-adrenergic blocking drugs have been discouraged in PAOD because of the 
possibility of worsening claudication symptoms. In a Cochrane review there was no 
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supporting evidence that beta blockers adversely affect walking distance in people with 
IC(18). However, due to the lack of large published trials beta blockers should be used with 
caution but are not contraindicated in PAOD.  
7. Diabetes mellitus 
Diabetes increases the risk of PAOD approximately three- to four-fold, and the risk of 
claudication two-fold. Diabetes is also associated with peripheral neuropathy which may lead 
to an increased risk of foot ulcers and foot infections. In recent years, there has been much 
discussion about the optimal treatment strategy of type 2 diabetes mellitus, aggressive or 
standard glucose lowering therapy. In a meta-analysis, an intensive glucose lowering regime 
(glycated haemoglobin level below 6.0%) was compared to standard therapy (targeted a level 
of 7.0-7.9%) in type 2 diabetes mellitus. Overall, intensive therapy significantly reduced 
coronary events without a significant effect on events of stroke or all-cause mortality(19). 
However, aggressive control of blood glucose levels (glycated haemoglobin level below 6.0%) 
is not recommended. The long term results of intensive therapy described a significantly 
reduced nonfatal myocardial infarction risk but an increased all-cause mortality rate (hazard 
ratio 1.21; 95% C.I. 1.02-1.44) after 5-year related with aggressive glucose lowering(20). TASC II 
recommends moderate aggressive control of blood glucose levels with an A1C goal of <7.0% 
and as close to 6.0% as possible (but not below 6%)(1). 
8. Hyperlipidemia 
In case of hyperlipidemia, dietary modification should be the initial intervention to control 
abnormal lipid levels. A 2007 Cochrane meta-analysis of mostly older trials that specifically 
evaluated patients with lower limb atherosclerosis concluded that lipid-lowering therapy 
reduced disease progression (improvement in total walking distance (Mean Difference (MD) 
152 m; 95% CI 32.11 to 271.88) and pain-free walking distance (WMD 89.76 m; 95% CI 30.05 
to 149.47) but no significant impact on ankle brachial index (WMD 0.04; 95% CI -0.01 to 
0.09)(21). It was concluded that lipid-lowering therapy is effective in reducing 
cardiovascular mortality and morbidity in people with PAOD. It may also improve local 
symptoms. Until further evidence on the relative effectiveness of different lipid-lowering 
agents is available, use of a statin in people with PAOD and a blood total cholesterol level ≥ 
3.5 mmol/litre is indicated. One of the largest included studies in this Cochrane review, the 
Heart Protection Study demonstrated the benefits of cholesterol-lowering statin therapy in 
6.748 patients with PAOD and 13.788 other high-risk participants, allocation to 40 mg 
simvastatin daily reduced the rate of the first major vascular events by about one-quarter, 
and that of peripheral vascular events by about one-sixth, with large absolute benefits seen 
in participants with PAOD because of their high vascular risk. Consequently, according to 
this study statin therapy should be considered for all patients with PAOD (all patients with 
total cholesterol level ≥ 3.5 mmol/L). This is in contrast to the older ACC/AHA guidelines as 
they recommended achieving an LDL cholesterol level <2.59 mmol/L (<100 mg/dL) in all 
patients with PAOD. In patients with PAOD and a history of other vascular disease (i.e., 
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coronary heart disease and cerebrovascular disease) it is reasonable to lower LDL 
cholesterol levels to 1.81 mmol/L (70 mg/dL)(11). Statins should be the primary lipid-
lowering agents to lower LDL cholesterol levels.  
9. Blood homocysteine 
Elevated homocysteine blood levels are associated with cardiovascular disease but it is 
uncertain whether this association is causal. Studies investigating the effects of folic acid 
supplementation on major vascular events in patients with peripheral arterial disease are 
lacking. However, long-term reductions in blood homocysteine levels with folic acid and 
vitamin B12 supplementation did not lead to a reduction of cardiovascular events and seems 
therefore not indicated according to a RCT including 12.064 survivors of myocardial 
infarction (22). 
10. Antiplatelet therapy 
Antiplatelet therapy reduces major vascular events (vascular death, nonfatal MI and 
nonfatal stroke) in patients with PAOD by 23%(23). Therefore, all symptomatic patients with 
or without a history of other cardiovascular disease should be prescribed antiplatelet 
therapy on the long term. Antiplatelet therapy is indicated to reduce the risk of MI, stroke 
and vascular death in individuals with symptomatic atherosclerotic lower extremity PAOD, 
including those with claudication. Aspirin is the antiplatelet agent of choice; clopidogrel 
may be used if aspirin cannot be tolerated or in the subgroup of patients with symptomatic 
PAOD(1). Unfortunately, adherence to cardiovascular medication is fairly low(24). Self-
reported consistent use (reported on ≥2 consecutive follow-up surveys and then through 
death, withdrawal, or study end) of cardiovascular medication was analysed using the Duke 
Databank for Cardiovascular Disease in patients with coronary artery disease with or 
without heart failure. In 2002, consistent use was reported: for aspirin, 71%; beta-blockers, 
46%; lipid-lowering therapy, 44%; aspirin and beta-blockers, 36%; and all three, 21%. For 
these reasons the assessment of medication compliance should be incorporated in the 
standard care for patients with PAOD, which is not the case in contemporary guidelines.  
11. Pharmacological therapy for Intermittent Claudication 
Pharmacologic treatment for relief of claudication symptoms typically involves other drugs 
than those used for risk reduction. Cilostazol is currently the most effective drug for IC(25). 
Approved by the FDA in 1999, the primary action of cilostazol is to inhibit 
phosphodiesterase type 3, which results in vasodilatation and inhibition of platelet 
aggregation, arterial thromboses and vascular smooth muscle proliferation. A three to six-
month course of cilostazol is a possible first line pharmacotherapy for the relief of 
claudication symptoms. One study with 2702 patients having stable moderate to severe 
claudication were randomly assigned to cilostazol or placebo. Patients treated with 100 mg 
cilostazol twice daily for 12 to 24 weeks experienced significantly greater increases in 
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supporting evidence that beta blockers adversely affect walking distance in people with 
IC(18). However, due to the lack of large published trials beta blockers should be used with 
caution but are not contraindicated in PAOD.  
7. Diabetes mellitus 
Diabetes increases the risk of PAOD approximately three- to four-fold, and the risk of 
claudication two-fold. Diabetes is also associated with peripheral neuropathy which may lead 
to an increased risk of foot ulcers and foot infections. In recent years, there has been much 
discussion about the optimal treatment strategy of type 2 diabetes mellitus, aggressive or 
standard glucose lowering therapy. In a meta-analysis, an intensive glucose lowering regime 
(glycated haemoglobin level below 6.0%) was compared to standard therapy (targeted a level 
of 7.0-7.9%) in type 2 diabetes mellitus. Overall, intensive therapy significantly reduced 
coronary events without a significant effect on events of stroke or all-cause mortality(19). 
However, aggressive control of blood glucose levels (glycated haemoglobin level below 6.0%) 
is not recommended. The long term results of intensive therapy described a significantly 
reduced nonfatal myocardial infarction risk but an increased all-cause mortality rate (hazard 
ratio 1.21; 95% C.I. 1.02-1.44) after 5-year related with aggressive glucose lowering(20). TASC II 
recommends moderate aggressive control of blood glucose levels with an A1C goal of <7.0% 
and as close to 6.0% as possible (but not below 6%)(1). 
8. Hyperlipidemia 
In case of hyperlipidemia, dietary modification should be the initial intervention to control 
abnormal lipid levels. A 2007 Cochrane meta-analysis of mostly older trials that specifically 
evaluated patients with lower limb atherosclerosis concluded that lipid-lowering therapy 
reduced disease progression (improvement in total walking distance (Mean Difference (MD) 
152 m; 95% CI 32.11 to 271.88) and pain-free walking distance (WMD 89.76 m; 95% CI 30.05 
to 149.47) but no significant impact on ankle brachial index (WMD 0.04; 95% CI -0.01 to 
0.09)(21). It was concluded that lipid-lowering therapy is effective in reducing 
cardiovascular mortality and morbidity in people with PAOD. It may also improve local 
symptoms. Until further evidence on the relative effectiveness of different lipid-lowering 
agents is available, use of a statin in people with PAOD and a blood total cholesterol level ≥ 
3.5 mmol/litre is indicated. One of the largest included studies in this Cochrane review, the 
Heart Protection Study demonstrated the benefits of cholesterol-lowering statin therapy in 
6.748 patients with PAOD and 13.788 other high-risk participants, allocation to 40 mg 
simvastatin daily reduced the rate of the first major vascular events by about one-quarter, 
and that of peripheral vascular events by about one-sixth, with large absolute benefits seen 
in participants with PAOD because of their high vascular risk. Consequently, according to 
this study statin therapy should be considered for all patients with PAOD (all patients with 
total cholesterol level ≥ 3.5 mmol/L). This is in contrast to the older ACC/AHA guidelines as 
they recommended achieving an LDL cholesterol level <2.59 mmol/L (<100 mg/dL) in all 
patients with PAOD. In patients with PAOD and a history of other vascular disease (i.e., 
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coronary heart disease and cerebrovascular disease) it is reasonable to lower LDL 
cholesterol levels to 1.81 mmol/L (70 mg/dL)(11). Statins should be the primary lipid-
lowering agents to lower LDL cholesterol levels.  
9. Blood homocysteine 
Elevated homocysteine blood levels are associated with cardiovascular disease but it is 
uncertain whether this association is causal. Studies investigating the effects of folic acid 
supplementation on major vascular events in patients with peripheral arterial disease are 
lacking. However, long-term reductions in blood homocysteine levels with folic acid and 
vitamin B12 supplementation did not lead to a reduction of cardiovascular events and seems 
therefore not indicated according to a RCT including 12.064 survivors of myocardial 
infarction (22). 
10. Antiplatelet therapy 
Antiplatelet therapy reduces major vascular events (vascular death, nonfatal MI and 
nonfatal stroke) in patients with PAOD by 23%(23). Therefore, all symptomatic patients with 
or without a history of other cardiovascular disease should be prescribed antiplatelet 
therapy on the long term. Antiplatelet therapy is indicated to reduce the risk of MI, stroke 
and vascular death in individuals with symptomatic atherosclerotic lower extremity PAOD, 
including those with claudication. Aspirin is the antiplatelet agent of choice; clopidogrel 
may be used if aspirin cannot be tolerated or in the subgroup of patients with symptomatic 
PAOD(1). Unfortunately, adherence to cardiovascular medication is fairly low(24). Self-
reported consistent use (reported on ≥2 consecutive follow-up surveys and then through 
death, withdrawal, or study end) of cardiovascular medication was analysed using the Duke 
Databank for Cardiovascular Disease in patients with coronary artery disease with or 
without heart failure. In 2002, consistent use was reported: for aspirin, 71%; beta-blockers, 
46%; lipid-lowering therapy, 44%; aspirin and beta-blockers, 36%; and all three, 21%. For 
these reasons the assessment of medication compliance should be incorporated in the 
standard care for patients with PAOD, which is not the case in contemporary guidelines.  
11. Pharmacological therapy for Intermittent Claudication 
Pharmacologic treatment for relief of claudication symptoms typically involves other drugs 
than those used for risk reduction. Cilostazol is currently the most effective drug for IC(25). 
Approved by the FDA in 1999, the primary action of cilostazol is to inhibit 
phosphodiesterase type 3, which results in vasodilatation and inhibition of platelet 
aggregation, arterial thromboses and vascular smooth muscle proliferation. A three to six-
month course of cilostazol is a possible first line pharmacotherapy for the relief of 
claudication symptoms. One study with 2702 patients having stable moderate to severe 
claudication were randomly assigned to cilostazol or placebo. Patients treated with 100 mg 
cilostazol twice daily for 12 to 24 weeks experienced significantly greater increases in 
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maximal and pain-free walking distances (50% and 67%, versus 22% and 40%, respectively) 
compared to the placebo group(25). Naftidrofuryl can also be considered. In a meta-analysis, 
naftidrofuryl showed an clinically meaningful improvement in pain-free and maximum 
walking distance in patients with IC(26). It is a 5-hydroxytryptamine type 2 antagonist and 
may improve muscle metabolism and reduce erythrocyte and platelet aggregation. 
Approval of cilostazol or naftidrofuryl for IC is however limited to certain countries.  
Other treatments are described such as the use of pentoxifylline (Trental). Pentotoxifylline is 
a rheologic modifier approved by the FDA for the symptomatic relief of claudication. Its 
mechanism of action includes an increase in red blood cell deformity wheras it decreases 
fibrinogen concentration, platelet adhesiveness, and whole-blood viscosity. The available 
data indicate that the benefit of pentoxifylline is marginal and not well established(11).  
Ginkgo biloba has been studied in patients with claudication with modest success. The 
mechanism by which ginkgo may work in this disorder is unclear, but may involve a 
number of activities including an antioxidant effect, inhibition of vascular injury, and 
antithrombotic effects. In a meta-analysis of 11 trials, patients who received ginkgo biloba 
extract had no significant differences in initial claudication distance. However, a trend 
toward improvement in the absolute claudication distance was observed. With the treadmill 
distances standardized between the protocols, a mean difference of 3.57 (95% CI -0.10-4.19) 
was found that corresponded to about 200 feet (64 meters), but the difference was not 
significant(27). The TASC guidelines concluded that no effect was proven(1). Several studies 
have evaluated the role of Vitamin E, chelation therapy, omega-3 fatty acids and estrogen 
therapies in the treatment of claudication. However, none of these therapies appeared 
effective(1). 
12. Exercise therapy 
Exercise therapy is the first suggested therapy for patients with IC. In 1898 the German 
neurologist Wilhelm Erb described successful results of exercise therapy for a patient with 
IC(28). The first randomised clinical trial (RCT) was performed by Larsen en Lassen in 
1966(29). In this study, 7 patients treated with exercise therapy were compared with a 
control group of 7 patients who were given ‘medical treatment’ in the form of lactose tablets. 
For the group treated with exercise, a significant increase in maximum walking time was 
observed whereas the patients in the control group did not improve.  
Nowadays, exercise therapy for patients with IC is extensively studied. In a Cochrane review 
by Watson et al. exercise therapy was compared with usual care or placebo regarding data of 
functional capacity outcome measurements(30). A total of twenty-two trials met the inclusion 
criteria involving a total of 1200 participants. Compared to placebo and usual care, exercise 
therapy significantly improved maximal walking time with a mean difference of 5.12 minutes 
(95% confidence interval 4.51 – 5.72) and an improved maximum walking distance of 113.2 
metres (range 95.0 to 131.4). Exercise therapy also showed a positive effect on the reduction of 
cardiovascular risk factors including hypercholesterolemia, hypertension, and diabetes 
mellitus.  
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The most common exercise therapy prescription consists of a single oral advice, usually 
without supervision or follow-up. The adherence of patients given an oral exercise advice 
appears to be low. Comorbidity, lack of (specific) advice, fear, and lack of discipline and 
supervision are barriers to actually perform regular walking exercise(31). For these reasons 
the importance of supervision was recognised.  
13. Supervised exercise therapy vs usual care (exercise therapy) 
Supervised exercise therapy (SET) entails adequate coaching by a physical therapist (PT) or 
an other exercise specialist (e.g. exercise physiologist, exercise therapist, specialised 
cardiovascular nurse) and aims to increase maximal walking distance, physical activity and 
health-related QoL. The most effective programs employ treadmill walking of sufficient 
intensity to cause claudication symptoms. Exercise is continued till near maximum pain, 
followed by rest, and then a next cycle of exercise is started over the course of a 30–60 
minute session. During the exercise session, treadmill exercise is performed at a speed and 
grade that will induce claudication symptoms. The patient should stop walking when 
claudication pain is considered moderate (a less optimal training response will occur when 
the patient stops at the onset of claudication). Exercise sessions are typically conducted three 
times a week for 3 months. A Cochrane review by Bendermacher et al. compared SET with 
non-supervised exercise programmes for patients with IC(32). SET showed statistically 
significant and clinically relevant differences in improvement of maximal walking distance 
compared with non-supervised exercise therapy regimens, with an overall effect size of 0.58 
(95% confidence interval 0.31 to 0.85) at three months. This translates into an improvement 
of approximately 150 meters of maximum walking distance in favour of the supervised 
group. However, additional studies on QoL are needed to definitely demonstrate clinical 
effectiveness. 
Another systematic meta-analysis comparing supervised to unsupervised exercise therapy 
showed a weighted mean difference in Pain Free Walking Distance (PWD) and Absolute 
Walking Distance (AWD) of 143.8 meters (95% CI; 5.8e281.8) and 250.4 meters (95% CI; 
192.4-308.5), respectively. The authors concluded that SET increased the PWD and AWD 
more than standard care(33). In a recent randomized controlled trial, three groups were 
compared: usual care (walk advice), home-based exercise and supervised exercise(34). 
Claudication Onset Time (COT) and Peak Walking Time (PWT) were compared after 3 
months. A significant improvement in COT and PWT were obtained in the exercise groups, 
but not in the usual care group (change after 3 months (sec): usual care; COT -16s, PWT -10s; 
home-based; COT 134s, PWT 124s; supervised; COT 165s, PWT 215s).  
14. Supervised exercise therapy vs endovascular revascularisation 
A recent systematic review compared (S)ET with percutaneous transluminal angioplasty 
(PTA) in patients with intermittent claudication (IC) to obtain the best estimates of their 
relative effectiveness(35). Eleven studies (reporting data on eight randomized clinical trials) 
met the inclusion criteria. One trial included patients with isolated aortoiliac artery 
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maximal and pain-free walking distances (50% and 67%, versus 22% and 40%, respectively) 
compared to the placebo group(25). Naftidrofuryl can also be considered. In a meta-analysis, 
naftidrofuryl showed an clinically meaningful improvement in pain-free and maximum 
walking distance in patients with IC(26). It is a 5-hydroxytryptamine type 2 antagonist and 
may improve muscle metabolism and reduce erythrocyte and platelet aggregation. 
Approval of cilostazol or naftidrofuryl for IC is however limited to certain countries.  
Other treatments are described such as the use of pentoxifylline (Trental). Pentotoxifylline is 
a rheologic modifier approved by the FDA for the symptomatic relief of claudication. Its 
mechanism of action includes an increase in red blood cell deformity wheras it decreases 
fibrinogen concentration, platelet adhesiveness, and whole-blood viscosity. The available 
data indicate that the benefit of pentoxifylline is marginal and not well established(11).  
Ginkgo biloba has been studied in patients with claudication with modest success. The 
mechanism by which ginkgo may work in this disorder is unclear, but may involve a 
number of activities including an antioxidant effect, inhibition of vascular injury, and 
antithrombotic effects. In a meta-analysis of 11 trials, patients who received ginkgo biloba 
extract had no significant differences in initial claudication distance. However, a trend 
toward improvement in the absolute claudication distance was observed. With the treadmill 
distances standardized between the protocols, a mean difference of 3.57 (95% CI -0.10-4.19) 
was found that corresponded to about 200 feet (64 meters), but the difference was not 
significant(27). The TASC guidelines concluded that no effect was proven(1). Several studies 
have evaluated the role of Vitamin E, chelation therapy, omega-3 fatty acids and estrogen 
therapies in the treatment of claudication. However, none of these therapies appeared 
effective(1). 
12. Exercise therapy 
Exercise therapy is the first suggested therapy for patients with IC. In 1898 the German 
neurologist Wilhelm Erb described successful results of exercise therapy for a patient with 
IC(28). The first randomised clinical trial (RCT) was performed by Larsen en Lassen in 
1966(29). In this study, 7 patients treated with exercise therapy were compared with a 
control group of 7 patients who were given ‘medical treatment’ in the form of lactose tablets. 
For the group treated with exercise, a significant increase in maximum walking time was 
observed whereas the patients in the control group did not improve.  
Nowadays, exercise therapy for patients with IC is extensively studied. In a Cochrane review 
by Watson et al. exercise therapy was compared with usual care or placebo regarding data of 
functional capacity outcome measurements(30). A total of twenty-two trials met the inclusion 
criteria involving a total of 1200 participants. Compared to placebo and usual care, exercise 
therapy significantly improved maximal walking time with a mean difference of 5.12 minutes 
(95% confidence interval 4.51 – 5.72) and an improved maximum walking distance of 113.2 
metres (range 95.0 to 131.4). Exercise therapy also showed a positive effect on the reduction of 
cardiovascular risk factors including hypercholesterolemia, hypertension, and diabetes 
mellitus.  
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The most common exercise therapy prescription consists of a single oral advice, usually 
without supervision or follow-up. The adherence of patients given an oral exercise advice 
appears to be low. Comorbidity, lack of (specific) advice, fear, and lack of discipline and 
supervision are barriers to actually perform regular walking exercise(31). For these reasons 
the importance of supervision was recognised.  
13. Supervised exercise therapy vs usual care (exercise therapy) 
Supervised exercise therapy (SET) entails adequate coaching by a physical therapist (PT) or 
an other exercise specialist (e.g. exercise physiologist, exercise therapist, specialised 
cardiovascular nurse) and aims to increase maximal walking distance, physical activity and 
health-related QoL. The most effective programs employ treadmill walking of sufficient 
intensity to cause claudication symptoms. Exercise is continued till near maximum pain, 
followed by rest, and then a next cycle of exercise is started over the course of a 30–60 
minute session. During the exercise session, treadmill exercise is performed at a speed and 
grade that will induce claudication symptoms. The patient should stop walking when 
claudication pain is considered moderate (a less optimal training response will occur when 
the patient stops at the onset of claudication). Exercise sessions are typically conducted three 
times a week for 3 months. A Cochrane review by Bendermacher et al. compared SET with 
non-supervised exercise programmes for patients with IC(32). SET showed statistically 
significant and clinically relevant differences in improvement of maximal walking distance 
compared with non-supervised exercise therapy regimens, with an overall effect size of 0.58 
(95% confidence interval 0.31 to 0.85) at three months. This translates into an improvement 
of approximately 150 meters of maximum walking distance in favour of the supervised 
group. However, additional studies on QoL are needed to definitely demonstrate clinical 
effectiveness. 
Another systematic meta-analysis comparing supervised to unsupervised exercise therapy 
showed a weighted mean difference in Pain Free Walking Distance (PWD) and Absolute 
Walking Distance (AWD) of 143.8 meters (95% CI; 5.8e281.8) and 250.4 meters (95% CI; 
192.4-308.5), respectively. The authors concluded that SET increased the PWD and AWD 
more than standard care(33). In a recent randomized controlled trial, three groups were 
compared: usual care (walk advice), home-based exercise and supervised exercise(34). 
Claudication Onset Time (COT) and Peak Walking Time (PWT) were compared after 3 
months. A significant improvement in COT and PWT were obtained in the exercise groups, 
but not in the usual care group (change after 3 months (sec): usual care; COT -16s, PWT -10s; 
home-based; COT 134s, PWT 124s; supervised; COT 165s, PWT 215s).  
14. Supervised exercise therapy vs endovascular revascularisation 
A recent systematic review compared (S)ET with percutaneous transluminal angioplasty 
(PTA) in patients with intermittent claudication (IC) to obtain the best estimates of their 
relative effectiveness(35). Eleven studies (reporting data on eight randomized clinical trials) 
met the inclusion criteria. One trial included patients with isolated aortoiliac artery 
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obstruction(36). In this MIMIC trial, patients were randomised to receive either PTA or no 
PTA against a background of SET and best medical therapy. The maximum walking 
distance was 75% greater in the PTA group (95%; CI 2-202) at 6 months and 78% greater in 
the PTA group (95%; CI 0-216) (p=0.05) at 24 months. No benefits were found for health-
related QoL. Unfortunately this trial did not evaluate results of SET alone versus PTA alone, 
so there is no evidence that angioplasty alone would produce similar results. 
In the review of Frans et al. three trials were included, which studied SET and PTA in 
femoropopliteal artery obstructions. In summary, SET with additional PTA gave the best 
improvement in Maximal Walking Distance (MWD), Initial Claudication Distance (ICD) and 
Ankle Brachial Index (ABI)(35). Changes in MWD, ICD and ABI between PTA alone and 
SET alone were equivocal, either comparable or in favour of PTA. QoL improved 
significantly during follow-up compared with baseline of all treatments, without differences 
between both groups.  
The systematic review additionally included five trials that studied combined lesions(35). In 
summary, PTA plus SET compared with PTA alone demonstrated an improvement in 
MWD. The two trials evaluating SET versus PTA had inconsistent results: one showed a 
benefit in terms of MWD and ICD after SET. The other trial demonstrated equal benefit in 
both groups. QoL data was assessed by seven different instruments with equivalent results. 
In conclusion there is not yet a well defined consensus for tailoring the optimal treatment for 
lesions at different anatomical locations. International guidelines (TASC II) still suggests to 
perform revascularisation when proximal lesions are suspected instead of prescribing SET 
and medical therapy. Unfortunately these guidelines may seem outdated. Results described 
above one could conclude that, in general, the effectiveness of PTA and SET was equivalent, 
although PTA plus SET improved walking distance and some domains of QoL scales 
compared with SET or PTA alone(35). Evidence to use a combination of PTA and SET for 
patients with IC complaints is still inconclusive. Moreover, cost-effectiveness data is still 
missing.  
In the United States, another large multicenter RCT was conducted(37). In this so called 
CLEVER trial, the researchers aimed to find the optimal treatment strategy for IC with 
endpoints being maximal walking duration and health-related QoL. They randomly 
assigned 111 patients with aortoiliac peripheral artery disease to receive 1 of 3 treatments: 
optimal medical care (OMC), OMC plus supervised exercise (SE), or OMC plus stent 
revascularization (ST). At the 6-month follow-up, the change in peak walking time (the 
primary end point) was greatest for SE, intermediate for ST, and least with OMC (mean 
change versus baseline, 5.8±4.6, 3.7±4.9, and 1.2±2.6 minutes, respectively; P<0.001 for the 
comparison of SE versus OMC, P<0.02 for ST versus OMC, and P<0.04 for SE versus ST). 
QoL improved with both SE and ST compared with OMC, for most scales, the extent of 
improvement was greater with ST than SE. The authors concluded that SE results in 
superior treadmill walking performance than ST, even for those with aortoiliac peripheral 
artery disease(37). The contrast between better walking performance for SE and better 
patient-reported quality of life for ST warrants further follow up.  
 
The Role of Supervised Exercise Therapy in Peripheral Arterial Obstructive Disease 65 
In conclusion, combining results of both studies, one could suggest that all patients with 
symptomatic PAOD should receive SET first as part of the initial treatment regimen, even 
patients with proximal lesions. In case of failing (patient dissatisfaction, disappointing 
results) an additional PTA could be suggested. However this treatment advice is based on 
moderate-level evidence, therefore results of two new trials have to be awaited (see section 
“future perspectives”).  
15. Supervised exercise therapy versus surgical reconstruction 
Only one RCT compared SET to surgical reconstruction(38). This study reported the initial 
evaluation of treatment efficiency in 75 patients with IC who were randomized to three 
treatment groups: 1) reconstructive surgery, 2) reconstructive surgery with subsequent 
physical training, and 3) physical training alone. The walking performance was improved in 
all three groups at follow-up, 13±0.5 months after randomization. Surgery was most 
effective, but the addition of training to surgery improved the symptom-free walking 
distance even further. However, no significant difference was found. Moreover, a higher 
complication rate and 3 deaths were observed in the surgical groups while no complications 
occurred in the trained group. Furthermore, the methodological quality of this trial could be 
questioned. 
16. Long term effects of supervised exercise therapy  
Few studies consider the long-term (>12 months) effects of SET. Gardner et al. tried to 
determine whether improvements in physical function after 6 months of SET could be 
sustained over a subsequent 12-months in older patients with IC(39). They concluded that 
improvements in maximum walking distance and physical activity level, after 6 months of 
exercise training, were prolonged for an additional 12 months period using a less intense 
exercise maintenance program. Ratliff et al. reported a 3-year follow-up of 212 patients with 
IC who initially were treated with SET with an exercise programme of two sessions a week 
for 10 weeks(40). Their results show that the maximum walking distance observed at 12 
weeks was still present at three years. Based on this limited experience, it appears that SET 
may have long term benefits for patients with IC.  
17. Supervised exercise therapy in hospital or community based setting  
An outpatient hospital setting was offered in the majority of all reviewed studies on SET. 
This approach may seem appropriate in trials but is associated with several limitations in 
daily clinical practise. First, the capacity of an exercise therapy program in an outpatient 
clinic is limited and not sufficient to provide SET for all patients with IC. Second, attending 
a hospital 3 times a week leads to a considerable transportation fee and is time-consuming 
for an individual patient. For this reason, implementation of a community-based SET 
program was instigated(41). The first results of a cohort study of patients treated with 
community-based SET resulted in a highly statistically significant improvement in 
 
Vascular Surgery – Principles and Practice 64 
obstruction(36). In this MIMIC trial, patients were randomised to receive either PTA or no 
PTA against a background of SET and best medical therapy. The maximum walking 
distance was 75% greater in the PTA group (95%; CI 2-202) at 6 months and 78% greater in 
the PTA group (95%; CI 0-216) (p=0.05) at 24 months. No benefits were found for health-
related QoL. Unfortunately this trial did not evaluate results of SET alone versus PTA alone, 
so there is no evidence that angioplasty alone would produce similar results. 
In the review of Frans et al. three trials were included, which studied SET and PTA in 
femoropopliteal artery obstructions. In summary, SET with additional PTA gave the best 
improvement in Maximal Walking Distance (MWD), Initial Claudication Distance (ICD) and 
Ankle Brachial Index (ABI)(35). Changes in MWD, ICD and ABI between PTA alone and 
SET alone were equivocal, either comparable or in favour of PTA. QoL improved 
significantly during follow-up compared with baseline of all treatments, without differences 
between both groups.  
The systematic review additionally included five trials that studied combined lesions(35). In 
summary, PTA plus SET compared with PTA alone demonstrated an improvement in 
MWD. The two trials evaluating SET versus PTA had inconsistent results: one showed a 
benefit in terms of MWD and ICD after SET. The other trial demonstrated equal benefit in 
both groups. QoL data was assessed by seven different instruments with equivalent results. 
In conclusion there is not yet a well defined consensus for tailoring the optimal treatment for 
lesions at different anatomical locations. International guidelines (TASC II) still suggests to 
perform revascularisation when proximal lesions are suspected instead of prescribing SET 
and medical therapy. Unfortunately these guidelines may seem outdated. Results described 
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improvement was greater with ST than SE. The authors concluded that SE results in 
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artery disease(37). The contrast between better walking performance for SE and better 
patient-reported quality of life for ST warrants further follow up.  
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In conclusion, combining results of both studies, one could suggest that all patients with 
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patients with proximal lesions. In case of failing (patient dissatisfaction, disappointing 
results) an additional PTA could be suggested. However this treatment advice is based on 
moderate-level evidence, therefore results of two new trials have to be awaited (see section 
“future perspectives”).  
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evaluation of treatment efficiency in 75 patients with IC who were randomized to three 
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physical training, and 3) physical training alone. The walking performance was improved in 
all three groups at follow-up, 13±0.5 months after randomization. Surgery was most 
effective, but the addition of training to surgery improved the symptom-free walking 
distance even further. However, no significant difference was found. Moreover, a higher 
complication rate and 3 deaths were observed in the surgical groups while no complications 
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Few studies consider the long-term (>12 months) effects of SET. Gardner et al. tried to 
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IC who initially were treated with SET with an exercise programme of two sessions a week 
for 10 weeks(40). Their results show that the maximum walking distance observed at 12 
weeks was still present at three years. Based on this limited experience, it appears that SET 
may have long term benefits for patients with IC.  
17. Supervised exercise therapy in hospital or community based setting  
An outpatient hospital setting was offered in the majority of all reviewed studies on SET. 
This approach may seem appropriate in trials but is associated with several limitations in 
daily clinical practise. First, the capacity of an exercise therapy program in an outpatient 
clinic is limited and not sufficient to provide SET for all patients with IC. Second, attending 
a hospital 3 times a week leads to a considerable transportation fee and is time-consuming 
for an individual patient. For this reason, implementation of a community-based SET 
program was instigated(41). The first results of a cohort study of patients treated with 
community-based SET resulted in a highly statistically significant improvement in 
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maximum walking distance (on a treadmill) after 3 and 6 months(42). The authors 
concluded that comparison of these results with historical studies on hospital-based SET 
should be done with caution due to the variability in the prescribed exercise regimens and 
used treadmill walking tests. However, SET in a community-based setting seemed to be at 
least as efficacious as programs that are provided in a clinical setting but with a higher 
capacity. 
18. Cost effectiveness of SET 
In a multicenter RCT ‘ExitPAD’ trial, Nicolaï et al. compared exercise therapy in the form of 
a ‘go home and walk’ advice (WA) with community-based SET for patients with IC(43). The 
data from this ExitPAD trial were also used to assess the cost-effectiveness of SET versus 
WA. For community-based SET, the incremental cost-effectiveness ratio for cost per QALY 
was €28,693. The Health Council of the Netherlands has determined that a QALY € 40,000 
may cost if the burden of disease for symptomatic PAOD is stated at a value of 0.5. At a 
willingness-to-pay threshold of this €40,000 SET seemed a cost-effective therapeutic option 
for patients with PAOD. In another randomized cost-effectiveness analysis SET was 
compared with endovascular revascularization (angioplasty with or without stenting)(44). 
This study was unfortunately underpowered so no significant difference was obtained. 
Endovascular revascularization leaded to a non-significant increase of 0.01 in QALYs (CI -
0.05 to 0.07). However a significant difference was demonstrated with respect to treatment 
costs. The costs for endovascular revascularization were significantly higher with a mean 
difference of € 2,318 per patient. In conclusion, endovascular revascularization was found 
cost effective if society would be willing to pay € 231,800 per QALY. This amount is far 
above the threshold of € 40,000. Therefore endovascular revascularization seems not cost 
effective compared with SET. 
Over the last decades, no international randomized cost-effectiveness analyses or health 
economic models were carried out to configure satisfying treatment strategies or guidelines. 
This while scientific evidence on the effectiveness of SET compared to endovascular 
revascularization has grown. Furthermore, the costs of endovascular revascularization will 
increase significantly as a result of technological innovations. SET seems the most cost-
effective treatment for symptomatic PAOD certainly if potential positive effects due to 
lifestyle changes on other vascular diseases (such as heart failure, myocardial infarction, 
stroke) and reduction of risk factors (such as hypertension, diabetes mellitus, and 
hyperlipidaemia) are taken into count. Further research into the extent of cost effectiveness is 
an urgent need for policy choices in modern health care (see section future perspectives)(45). 
19. Future perspectives 
Although SET is considered the best evidence based therapy for all patients with IC, general 
practitioners, vascular surgeons or vascular specialists do not always have the disposal of 
(community-based) physical or exercise therapists (PTs) with specific knowledge of IC or 
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exercise training. Also, not all PT’s have sufficient experience with this specific patient 
category. Patients suffer from a variety of comorbidities and modifiable lifestyle factors, 
potentially generating suboptimal results. Unfortunately, too many examples of PT’s treating 
patients with IC with massage and other alternative, non evidence based treatments exist.  
In an ideal situation, all patients with symptomatic PAOD should receive an evidence based 
standardised form of SET by an exercise specialist. Due to lack of capacity, hospital-based 
exercise therapy should be reserved for cases with severe (cardiac) comorbidity. For this 
reason the ClaudicatioNet concept was launched in the Netherlands in January 2011. 
ClaudicatioNet is a concept representing an integrated care network between PTs, vascular 
surgeons and general practitioners. ClaudicatioNet aims to implement nationwide coverage 
of regional networks providing transparent, synergistic and multidisciplinary care 
according the guidelines of cardiovascular risk management and SET.  
Two Dutch multicenter RCT’s are including patients to evaluate the effectiveness and cost-
effectiveness of SET. The ERASE-trial compares SET with a PTA complementary to SET. The 
optimal treatment strategy for IC due to an iliac artery obstruction will be determined in the 
SUPER-trial. The SUPER-trial compares the (cost-) effectiveness of initial PTA versus initial 
SET in patients with disabling IC due to an iliac artery obstruction. Results have to be 
awaited. 
Although there is little evidence yet, SET could also be effective for patients with critical 
limb ischemia as an adjuvant to a revascularisation procedure. Badger et al. evaluated the 
efficacy of an exercise program following arterial bypass surgery for short distance IC or 
critical ischemia(46). SET resulted for this group in an increased maximum walking distance 
of 175% compared to 4% for the group with usual care. These studies indicate that SET is a 
useful adjunct after a PTA or lower limb bypass surgery. In the Netherlands the PEARL 
study is designed to confirm the clinical effectiveness of SET after a vascular intervention for 
the subgroup of patients with critical limb ischemia. 
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1. Introduction 
Lower limb varicose veins are a common disease that affects almost a quarter of the adult 
population. They are one of the commonest conditions requiring intervention. They affect 
women more frequently than men, and are reported in 20-60% of the general population. 
Approximately one million people in the United Kingdom are affected with VV. Nearly half 
a million seek advice from their primary care practitioner about VV in the lower limbs and 
their related symptoms every year. Of those, 75,000 patients receive some form of 
intervention. It is estimated that surgical treatment of varicose veins are responsible for 
54000 hospital episodes per year in England. They constitute a large part of elective surgical 
waiting lists [1, 2 and 3]. 
The treatment of primary varicose veins is considered appropriate by the majority of 
vascular surgeons if the veins are symptomatic. Common symptoms include poor cosmesis, 
aching and itching. Less common problems are haemorrhage, thrombophlebitis, ankle 
pigmentation, lipodermosclerosis and ulceration. The extent of visible veins does not 
correlate with the severity of the symptoms experienced by patients [4]. 
Treatment options available for varicose veins traditionally included either conservative 
management with lifestyle advice and compression hosiery or surgery. Surgery involves 
saphenofemoral junction disconnection and stripping of the long saphenous vein and 
multiple stab avulsions for varicose veins stemming from saphenofemoral reflux; 
saphenopopliteal disconnection for saphenopopliteal reflux [2]. 
Results from traditional surgery are excellent and have stood the test of time. However, 
there has been an expansion of less invasive treatment modalities for VV, such as 
radiofrequency ablation, endovenous laser treatment, sclerotherapy (liquid and foam), 
transilluminated powered phlebectomy, and subfascial endoscopic perforator vein surgery. 
These minimally invasive therapies are attractive to both patients and healthcare 
professionals but there is paucity of good quality data from randomized control trials [5]. 
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Moreover, the need for specialized equipment and additional training to become proficient 
at new techniques, prevent surgeons from practicing these procedures. 
In the United Kingdom, until there is long-term follow-up with the less invasive procedures, 
the gold standard for VV surgery is still a standard saphenofemoral junction ligation and 
disconnection (SFJLD) with stripping of the long saphenous vein and multiple stab 
avulsions. As stripping of the long saphenous vein is painful, this surgery requires a general 
anaesthetic and an overnight in-patient stay for satisfactory recovery. 
We propose a new approach to addressing problems with VV in the lower limb that 
obviates the need for a general anaesthesia. After SFJLD, the varicosities in the long 
saphenous system are rarely fed retrogradely unless there are incompetent perforators—
thus, varicosities in the lower limb would be expected to diminish in size and length. If the 
long saphenous vein is left in situ without stripping and stab avulsions are not done at the 
time of groin exploration for SFJLD, VV surgery can be done safely under local anaesthetic. 
Currently, we perform multiple stab avulsions (under local anaesthetic) as a second-stage 
procedure at 6 months post-SFJLD. 
The purpose of this study was twofold. The first aim was to study the longitudinal 
functional and cosmetic outcome in a consecutive series of patients who had SFJLD under 
local anaesthetic. Our second aim was to identify the optimum time gap from SFJLD to 
multiple stab avulsions for residual VV. 
2. Methods 
A prospective observational study was designed by the Scarborough General Hospital 
Vascular team. It was carried out between June 2006 and June 2008. 
The patients were recruited in two different out patient clinics, including Scarborough 
General Hospital Outpatient department and Malton County Hospital Outpatient 
Department. Both clinics were supervised by a single Consultant Vascular Surgeon. 
A very specific inclusion criteria was devised to select the patients to be included in this 
study: 
1. Patients met the National Institute of Clinical Excelence guidelines for treatment of 
Varicose Veins. 
2. Patients with clinical evidence of Primary varicose veins of the Long Saphenous Vein 
distribution. 
3. All patients had clinical and ultrasonographic evidence of incompetence at the 
Saphenofemoral junction. This was demonstrated using, either a Hand Held Doppler 
Machine or a Venous Duplex Ultrasound Scan. 
4. All patients were suitable for Local Anaesthetic Surgery in a day case setting    
- Patients had a BMI less than 35 
- Patients had transport arranged to go back home as they were not allowed to drive 
themselves 
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- Patients had a responsible carer to look after them postoperatively 
- Patients were ASA (American Society of Anaesthesiologist Classification) I, II or III 
- Patient/Carer must have access to a private telephone 
- Patients residence must be within one and a half hour of a Hospital with Accident 
and Emergency and Vascular facilities 
Exclusion criteria included 
1. Pregnancy 
2. Age below 18 years 
3. Allergy to Local Anaesthetic Agents 
4. Patients with Varicose veins of the Short Saphenous System distribution 
5. Recurrent Varicose Veins 
6. Patients with complex varicosities 
7. Previous history of Deep Vein Thromboembolis 
8. Areas of active ulceration (CEAP Classification C6) 
2.1. Veins and questionnaire assessment 
Suitable patients were seen preoperatively in the Outpatient Clinic. All the visible varicose 
veins were marked with a permanent ink pen. After that, the length of varicosities was 
measured using a cartographer's wheel (Figure 1) 
The outer ring of the cartographer's ring measures the length of varicosities in centimetres 
and gives us an accurate measurement of the extension of the Varicose Veins. This 
measurement was done by a single assessor. 
A higher measurement on the wheel cartograph meant a greater volume of varicose veins. 
Every patient taking part in the trial was asked to fill up four standardized health 
questionnaires: 




C Clinical signs (grade 0-6) supplemented by (s) for symptomatic and (a) for 
asymptomatic presentation 
E Ethiological Classification (Congenital, Primary, Secondary) 
A Anatomical Distribution (Superficial, Deep, Perforator) 
P Pathophysiology Dysfunction (Reflux, Obstruction) 
 
Table 1. Classification of chronic lower extremity venous disease. CEAP score 
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Moreover, the need for specialized equipment and additional training to become proficient 
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Figure 1.  
 
Class Cinical signs
0 No visible or palpable signs of venous disease
1 Telangiectases, reticular veins, malleolar flare
2 Varicose Veins
3 Oedema without skin changes
4 Skin changes ascribed to venous disease (pigmentation,venous eczema, lipodermatosclerosis)
5 Skin changes in conjunction with healed ulceration
6 Skin changes in conjunction with active ulceration
Table 2. CEAP Clinical classification of chronic lower extremity venous disease 
2. Venous clinical severity score 
 
Attribute Absent = 0 Mild = 1 Moderate = 2 Severe = 3 
Pain None Occasional Daily Limit activities 
Varicose veins None Few, scattered Multiple (LSV) Extensive (LSV, SSV) 
Venous Oedema None Evening, Ankle Afternoon, leg Morning, leg 
Pigmentation None Limited area Wide (lower 1/3) Wider (Above 1/3) 
Inflamation None Cellulitis Cellulitis Cellulitis 
Induration None Focal (<5 cm) <lower 1/3 Entire lower 1/3 
Number of AC None 1 2 3
Duration of AC None <3 months 3 months- 1 year >1 year
Size of AC None <2 cm diameter 2-6 cm diameter >6 cm diameter 
Comp therapy Not used Intermittent use Most days Continually 
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3. Aberdeen varicose vein severity score 
1. Please draw in your varicose veins in the diagram below: Vein grid 
2. In the last two weeks, for how many days did your varicose veins cause you pain or 
ache? 
3. during the last two weeks, on how many days did you take painkilling tablets for your 
varicose veins? 
4. In the last two weeks, how much ankle swelling have you had? 
5. In the last two weeks, have you worn support stockings or tights? 
6. In the last two weeks, have you had any itching in association with yourvaricose veins? 
7. Do you have purple discolouration caused by tiny blood vessels in the skin, in 
association with your varicose veins? 
8. Do you have a rash or eczema in the area of your ankle? 
9. Do you have a skin ulcer associated with your varicose veins? 
10. Does the appearance of your varicose veins cause you concern? 
11. Does the appearance of your varicose veins influence your choice of clothing including 
tights? 
12. During the last two weeks, have your varicose veins interfered with your 
work/housework or other daily activities? 
13. During the last two weeks, have your varicose veins interfered with your leisure 




SF-36 Health survey 
Instructions for completing the questionnaire: Please answer every question. Some
questions may look like others, but each one is different. Please take the time to read and
answer each question carefully by filling in the bubble that best represents your response. 
Patient Name: __________________________________________________________ 
SSN#: _____________________________________ Date: _____________________________ 
Person heling to complete this form: _______________________________________________ 
1. In general, would you say your health is: 
q Excellent 




2. Compared to one year ago, how would you rate your health in general now? 
q Much better now than a year ago 
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q Somewhat better now than a year ago 
q About the same as one year ago 
q Somewhat worse now than one year ago 
q Much worse now than one year ago 
3. The following items are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much? 
a. Vigorous activities, such as running, lifting heavy objects, participating in strenuous
sports. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
b. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or
playing golf? 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
c. Lifting or carrying groceries. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
d. Climbing several flights of stairs. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
e. Climbing one flight of stairs. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
f. Bending, kneeling or stooping. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
SF-36 2 
g. Walking more than one mile. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
h. Walking several blocks. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
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i. Walking one block. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
j. Bathing or dressing yourself. 
q Yes, limited a lot. 
q Yes, limited a little. 
q No, not limited at all. 
4. During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of your physical health? 
a. Cut down the amount of time you spent on work or other activities? 
c Yes c No 
b. Accomplished less than you would like? 
c Yes c No 
c. Were limited in the kind of work or other activities 
c Yes c No 
d. Had difficulty performing the work or other activities (for example, it took extra time) 
c Yes c No 
5. During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
a. Cut down the amount of time you spent on work or other activities? 
c Yes c No 
b. Accomplished less than you would like 
c Yes c No 
c. Didn't do work or other activities as carefully as usual 
c Yes c No 
6. During the past 4 weeks, to what extent has your physical health or emotional problems
interfered with your normal social activities with family, friends, neighbors, or groups? 
q Not at all 
q Slightly 
q Moderately 
q Quite a bit 
q Extremely 
7. How much bodily pain have you had during the past 4 weeks? 
q Not at all 
q Slightly 
q Moderately 
q Quite a bit 
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q Extremely 
SF-36 3 
8. During the past 4 weeks, how much did pain interfere with your normal work (including
both work outside the home and housework)? 
q Not at all 
q Slightly 
q Moderately 
q Quite a bit 
q Extremely 
9. These questions are about how you feel and how things have been with you during the
past 4 weeks. For each question, please give the one answer that comes closest to the way
you have been feeling. How much of the time during the past 4 weeks. 
a. did you feel full of pep? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time 
b. have you been a very nervous person? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time 
c. have you felt so down in the dumps nothing could cheer you up? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time 
d. have you felt calm and peaceful? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time
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e. did you have a lot of energy? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time 
f. have you felt downhearted and blue? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time 
SF-36 4 
g. did you feel worn out? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time 
h. have you been a happy person? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time 
i. did you feel tired? 
q All of the time 
q Most of the time 
q A good bit of the time 
q Some of the time 
q A little of the time 
q None of the time 
10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.)? 
q All of the time 
q Most of the time 
q Some of the time 
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q Extremely 
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q A little of the time 
q None of the time 
11. How TRUE or FALSE is each of the following statements for you? 
a. I seem to get sick a little easier than other people 
q Definitely true 
q Mostly true 
q Don't know 
q Mostly false 
q Definitely false 
b. I am as healthy as anybody I know 
q Definitely true 
q Mostly true 
q Don't know 
q Mostly false 
q Definitely false 
c. I expect my health to get worse 
q Definitely true 
q Mostly true 
q Don't know 
q Mostly false 
q Definitely false 
d. My health is excellent 
q Definitely true 
q Mostly true 
q Don't know 
q Mostly false 
q Definitely false 
The clinical component from CEAP scores ranges from 0 to 6; Higher scores denote greater 
severity. 
The VCSS consist of clinical variables, each ranging from 0(none) to 3 (severe). Thus, the 
VCSS ranged form 0 to 30; Higher scores denote greater severity of varicose veins. 
The AVVSS assessment consisted of 13 clinical variables and the completion of a vein grid. 
Each question was given a weighted score. For each limb, the AVVSS produced a score 
ranging from 0 to 50; Higher scores meant greater severity of Varicose Veins. 
The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-
scale profile of functional health and well-being scores as well as psychometrically-based 
physical and mental health summary measures and a preference-based health utility index. 
It is a generic measure, as opposed to one that targets a specific age, disease, or treatment 
group. Accordingly, the SF-36 has proven useful in surveys of general and specific 
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populations, comparing the relative burden of diseases, and in differentiating the health 
benefits produced by a wide range of different treatments. 
3. Operative details 
The procedure was carried out by, or supervised by, a single consultant. 
Patients were prepared with non alcoholic povidone-iodine and drapped with sterile 
disposable materials. 
1% Lignocaine with Adrenaline was used to anaesthesize the groin and perform a Ilio-
inguinal nerve block, according with the guidelines of Local Anaesthetic use [11] (Figure 2) 
 
Figure 2.  
The incision in the groin is placed medial to the Femoral pulse and 1 centimetre above the 
inguinal crease. 
The dissection begins with the identification of the Long Saphenous Vein and the Sapheno-
Femoral junction where the Long Saphenous Vein joins the Deep Femoral Vein. All 
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tributaries of the Long Saphenous Vein are tied with 3.0 Vicryl sutures (Ethicon Inc 
Somerville, NJ). Smaller tributaries are dealt with Bipolar Diathermy. The proximal end of 
the Long Saphenous Vein is suture-ligated with 1.0 Vicryl and disconnected 0.5 cm flush 
from the Deep Femoral Vein. 
Fascial layers are closed with interrupted 2.0 Vicryl sutures and the skin approximated with 
2.0 Monocryl sutures (Ethicon Inc., Somerville, NJ). 
Patients go back to the Day Unit where they are observed for 2 hours after their proedure 
and discharged from the Unit provided there are not complications. 
3.1. Follow up 
All patients who had Sapheno-Femoral junction Ligation and Disconnection(SFJLD) under 
Local Anaesthetic were reviewed in the Outpatient Department at 1,3 and 6 months 
postoperatively. At each of this times, the veins were examined clinically, marked and 
measured with the cartographer's wheel and the four questionnaires were repeated. 
After a final assessment post- SFJLD, patients are listed for Multiple Stab Avulsions under 
Local Anaesthetic. 
A three month Outpatient Department appointment is given to every patient for futher 
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On maximum follow-up, six (13%) patients had recurrent VV. Of these, two patients opted 
for redo surgery. This consisted of re-exploration of the groin and stripping of the long 
saphenous veins under a general anaesthetic. 
 
Figure 7. Follow-up of Short Form 36 scores after surgery. 
4. Discussion  
The results from present study suggest that SFJLD under local anaesthetic confers 
symptomatic and cosmetic improvement 1 month after the procedure. Improvements are 
sustained on early follow-up, thereby allowing multiple stab avulsions to be performed as a 
staged procedure within 6 months of the index procedure. 
Currently, there is an increasing demand and need for VV surgery. Despite this demand, 
waiting lists are increasingly “controlled” and the funding is “regulated” by primary care 
trusts because VV are deemed to be a cosmetic disease without any life-threatening 
consequences. Ligation of the great saphenous vein at the SFJ, with or without stripping, is a 
long described method of VV surgery with varying successes [12, 13, 14]. We believe that 
SFJLD under a local anaesthetic, is a feasible procedure for VV disease, particularly for those 
with early disease. There are several advantages. Our method does not require a general 
anaesthetic and the procedure can be done as a day case without an in-patient stay. As such, 
surgery for VV can be done in peripheral cottage hospitals where specialized equipment 
and support from anaesthetic colleagues may be unavailable. The shift of work to peripheral 
hospitals reduces the demand and pressure on waiting list in larger central hospitals where 
general anaesthetic lists are being done. 
The results obtained from the various VV questionnaires were reassuring. The procedure 
used in the present study resulted in significant cosmetic and functional improvement on 
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short-term follow-up. We saw significant improvements with all three VV-specific 
questionnaires (CEAP, VCSS, and AVVSS questionnaire). Although the AVVSS 
questionnaire was initially designed to assess severity of varicosities in both lower limbs, we 
were still able to use it for unilateral assessment. The assessment was performed 
unilaterally in our series of patients because the total volume of local anaesthetic that was 
used for the procedure was often the limiting factor in surgery. Results from the SF-36 
questionnaire have to be interpreted with caution. We noted significant improvements in 
quality of life up to 6 months postoperatively. The SF-36 is a global quality of life 
questionnaire, which may not be sensitive enough to detect improvements in quality of 
life as a direct consequence of VV surgery. However, to date, we are unaware of a more 
specific quality of life questionnaire, which has been designed for patients who 
underwent VV surgery. 
There were several limitations to our study. First, the size of our patient population was 
small. We have been selective in the recruitment of patients for this study. Patients in our 
study had simple VV with minimal chronic venous changes; thus, they were patients who 
had early VV. We did not perform Duplex studies in any patients preoperatively. Certainly, 
the rates of early recurrent VV in our study are higher than conventional studies and this 
may be secondary to our failure to perform Duplex studies. This would have identified the 
anatomy of the long saphenous veins and potential perforators associated with it.  
To further validate the study it may have been useful to have pre- and postoperative formal 
Duplex studies for comparison and to help explain disease recurrence. The reported rate of 
clinical recurrence ranges from 20 to 80% after a period between 5 and 20 years [15]. The 
average time between the first and the second surgical treatments is long ranging, from 6 to 
20 years [16, 17]. 
As long-term data are lacking in our series, our recurrence rate of 13% at maximum 3 years 
follow-up may underestimate total disease recurrence. At 2 years follow-up, a recurrence 
rate of 16% was demonstrated by clinical and Duplex evaluation in a study by Coufinhal 
[18] 
The rate of disease recurrence increases with time, probably because of progression of the 
disease. Kostas et al identified three main causes of disease recurrence [19]. The first was 
attributable to inadequate initial treatment and results in recurrence in 55-70% of cases. It 
arises either as a result of failure in identifying all incompetent veins or a failure in carrying 
out adequate primary treatment. The second group of causes arises from disease 
progression resulting in development of varices in previously normal veins and accounting 
for 20-25% of recurrences. The third cause of recurrence is neovascularization, in which 
varices arise in the track of previously stripped or ligated veins and account for 5-25% of 
recurrences. Dissection of the tributary vessels at the SFJ may contribute to our early rates of 
recurrence. Taking vessels back beyond the primary, or even the secondary tributaries, may 
be a cause of neovascularization in the groin. Duplex ultrasound surveillance has supported 
this finding [20]. 
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5. Conclusion 
SFJLD under local anaesthetic is a suitable procedure with early VV. Patients who undergo 
this procedure show improvement in cosmesis and function. However, on short-term 
follow-up, it appears to be associated with higher rates of recurrent VV when compared 
with conventional techniques. 
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1. Introduction 
A pseudoaneurysm refers to a defect in an arterial wall, which allows communication of 
arterial blood with the adjacent extra-luminal space. Blood extravasates out of the artery, but 
is contained by surrounding soft tissue and compressed thrombus which form a cavity or 
sac.[1] There is often a narrow tract stemming from the arterial wall to the pseudoaneurysm 
sac, termed the ‘neck’. A pseudoaneurysm is distinct from a ‘true’ aneurysm, which results 
from dilation of all layers of the arterial wall.  
Pseudoaneurysms are typically the result of traumatic arterial injury. With the increasing 
utilisation of percutaneous arterial interventions worldwide, iatrogenic arterial injury has 
become the predominant cause of pseudoaneurysm formation. The highest incidence of 
iatrogenic pseudoaneurysm formation is observed in the common femoral artery as a result 
of inadequate seal of the arterial puncture site following catheterisation procedures. It is 
reported that femoral pseudoaneurysms occur in up to 0.2% of diagnostic and 8% of 
interventional procedures.[2) Approach to the management of a pseudoaneurysm depends 
on its anatomical location. This chapter will focus primarily on the management of 
iatrogenic femoral pseudoaneurysms, with an overview of other peripheral and visceral 
iatrogenic pseudoaneurysms. 
2. Femoral iatrogenic pseudoaneurysms 
2.1. General considerations 
Factors which may increase the risk of iatrogenic femoral pseudoaneurysm formation after 
femoral catheterisation can be broadly categorised into procedural or patient factors. 
‘Procedural’ factors include low femoral puncture, inadvertent catheterisation of the 
superficial femoral artery or profunda femoris artery, interventional rather than diagnostic 
procedures, and inadequate compression following removal of the sheath. ‘Patient’ factors 
include obesity and the need for anticoagulation post-procedure.[2] 
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Patients with femoral pseudoaneurysms typically present with pain and swelling of the 
affected groin, along with a palpable mass which may be pulsatile with a thrill or bruit.[1] 
Clinical diagnosis can usually be made in slim patients, but can be difficult in those who are 
obese, where a high index of suspicion is required to prompt further investigation. Small 
pseudoaneurysms may resolve spontaneously without intervention. Pseudoaneurysms 
which persist may enlarge and lead to complications related to compression of the adjacent 
femoral vein, nerve, and overlying skin. This can lead to leg swelling, deep vein thrombosis, 
compressive neuropathy and skin necrosis. Although rare, pseudoaneurysms may also 
expand and eventually rupture.[3] 
2.2. Diagnosis 
Duplex ultrasonography (DUS) is the modality of choice for diagnosis of femoral 
pseudoaneurysms, particularly in centres with a dedicated vascular ultrasound 
laboratory.[4] DUS has been reported to have a sensitivity of 94% and a specificity of 97% in 
the detection femoral pseudoaneurysms.[5] Compared to other imaging techniques, DUS is 
safe and non-invasive. It can also be performed at the bedside. Clear views of the femoral 
vessels and associated pathology can be achieved rapidly in experienced hands. Another 
advantage of DUS is that definitive treatment (discussed later) can be performed in the same 
session. 
On DUS, a pseudoaneurysm appears as a hypoechoic sac adjacent to the affected artery, 
with colour flow observed within it. Thrombus may be identified within part of the sac. The 
hallmark of diagnosis is the demonstration of a neck communicating between the sac and 
the affected artery, with a ‘to-and-fro’ waveform.[1] The ‘to’ representing blood flow into 
the pseudoaneurysm and the ‘fro’ representing blood flow out of the pseudoaneurysm. 
Waveform analysis of the affected artery is useful to establish a baseline for subsequent 
comparison. The adjacent vein should be inspected for compression or the presence of 
thrombus.  
Computed Tomography Angiography (CTA) is another effective diagnostic modality, 
particularly in centres without ready access to vascular ultrasound services. It is also useful 
in cases where duplex ultrasound findings are equivocal or the anatomy is not well 
defined.[2] CTA allows accurate assessment of the pseudoaneurysm, its surrounding 
structures, arterial inflow and distal run-off to the leg. Drawbacks of CTA include radiation 
exposure (of particular concern in younger patients) and use of iodinated contrast agents 
(with risk of anaphylaxis and nephropathy).[6] Use of contrast is important to establish that 
active flow is present within the pseudoaneurysm cavity, which would be otherwise 
indistinguishable from a haematoma. Patients with mild renal impairment can be pre-
hydrated before a CTA to minimise the risk of nephropathy. In those with moderate to 
severe renal impairment, alternative imaging should be considered.[6] 
Magnetic Resonance Angiography (MRA) has emerged as an alternative to CTA in recent 





surrounding structures. Problems with the technique include availability, time duration and 
cost. In patients with allergies to iodinated contrast, MRA is a potential alternative imaging 
technique.[1] Gadolinium-based agents are also associated with the rare complication of 
nephrogenic systemic fibrosis in patients with impaired renal function which should be 
considered as a relative contra-indication.[6]  
2.3. Approach to management 
A proportion of iatrogenic femoral pseudoaneurysms will resolve spontaneously without 
any form of intervention. An accepted approach is to monitor small (less than 3cm), stable, 
asymptomatic pseudoaneurysms, as the majority of them will thrombose within 4 weeks.[7] 
In one large series of small (<3cm) pseudoaneurysms, Toursarkissian et al reported a rate of 
spontaneous thrombosis of ~90% at 60 days of follow-up.[7] However, the need for regular 
follow-up resulting in possible delayed discharge from the hospital, and difficulty in 
patients reducing their activity while awaiting pseudoaneurysm resolution, has led to the 
early active management of most pseudoaneurysms.[2] An exception may be for very small 
(<1cm), stable, asymptomatic pseudoaneurysms, which could be managed conservatively 
with repeat imaging at one week after diagnosis to see if spontaneous thrombosis has 
occurred. In addition, spontaneous thrombosis of the pseudoaneurysm may be less likely in 
patients who are fully anticoagulated or receiving combination antiplatelet therapy, where 
active management is preferred. 
Traditionally, most iatrogenic femoral pseudoaneurysms requiring intervention were 
treated with open surgical repair. With the increasing availability of DUS during the 1990s, 
less invasive treatment options using DUS-guidance gained popularity. These methods 
included ultrasound-guided compression (UGC) and percutaneous ultrasound-guided 
thrombin injection (UGTI). [8,9] 
Open surgical repair (OSR) has traditionally been considered the ‘gold standard’ treatment 
for iatrogenic femoral pseudoaneurysms, as the arterial defect is repaired definitively. 
Principle steps of OSR involve obtaining proximal and distal control of the affected artery, 
evacuating the aneurysm sac and repairing the defect in the arterial wall (either by primary 
or patch closure).[10]  Complications of OSR include blood loss and infection. Other major 
adverse events such as myocardial infarction or death are recognised. In high cardiac risk 
patients, OSR may be performed under local or regional anaesthesia. Recovery time and 
inpatient stay may be prolonged following OSR. 
The advent of less invasive treatment strategies utilising ultrasound (discussed later), have 
led to a paradigm shift in treatment strategies. OSR is now typically reserved for emergency 
situations such as rapidly expanding pseudoaneurysms, ruptured pseudoaneurysms, 
pseudoaneurysms causing mass effect (with overlying skin ischaemia or neurovascular 
compromise), or when other treatment options have failed.[11] Infective complication of 
iatrogenic femoral pseudoaneurysms are less common but represent a distinct entity which 
require open surgical treatment over other interventional techniques and will be considered 
later in this chapter. 
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2.3.1. Ultrasound-Guided Compression 
Ultrasound-Guided Compression (UGC) of pseudoaneurysms to induce thrombosis of the 
aneurysm sac was proposed as an alternative to surgery by Fellmeth et al in 1991.[8] 
Principles of UGC involve locating the aneurysm sac using the ultrasound transducer and 
applying enough pressure to stop flow within the sac, but maintain flow in the affected 
artery.[5] Flow within the sac is reassessed at 10 - 20 minute intervals until thrombosis is 
achieved.[1] Unfortunately, efficacy of this technique is limited, with success rates between 
62% - 86%.[1,2] Compression times can also be lengthy. This occupies vascular ultrasound 
laboratory resources and can be uncomfortable for both the patient and clinician.[9] Other 
problems include incompressible pseudoaneurysms, limited success in patients being treated 
with anticoagulants & some early recurrences.[9] Despite this, before other minimally invasive 
treatment options were available, Perkins et al reported that UGC reduced the need for open 
surgery by about 50%, avoiding the associated risks of surgery in these patients.[9] 
2.3.2. Ultrasound-Guided Thrombin Injection 
Ultrasound-Guided Thrombin Injection (UGTI) of pseudoaneurysms is a technique first 
described by Kang et al in 1998.[12] The technique involves needle infiltration of the 
aneurysm sac using ultrasound guidance and injection of thrombin to induce thrombosis of 
the cavity. Previously published studies have documented rates of thrombosis between 86 - 
100% (the majority successful on the first attempt).[2] The procedure has the advantage of 
being relatively quick and simple. The most serious complication of UGTI is distal arterial 
embolisation, which is a relatively rare outcome (less than 2% in reported series). If this 
occurs, intra-arterial thrombolysis may be undertaken.[13] 
At the Oxford University Hospitals, UGTI has been used as first-line therapy for the 
treatment of iatrogenic femoral pseudoaneurysms. Between August 2005 and July 2011, 94 
patients underwent UGTI for treatment of iatrogenic pseudoaneurysms. Patients were 
included in a prospective registry and underwent follow up DUS examination to assess 
treatment efficacy. 97% of pseudoaneurysms suitable for UGTI were successfully treated by 
this technique, avoiding the risks associated with surgical repair. 91.1% of treatments were 
successful on the first attempt, and no significant complications were recorded.  
In our experience, we have found UGTI to be a simple, quick and safe technique for the 
treatment of suitable pseudoaneurysms. For small pseudoaneurysms (<1cm), a repeat DUS 
was performed one week later to see if spontaneous thrombosis had occurred. 
Pseudoaneurysms with a neck width >1cm were not treated by this method, as wide necks 
may be related to higher risk of thromboembolic complications.[14] Given the availability of 
DUS in most major vascular surgery units, UGTI should be the treatment of choice for all 
suitable iatrogenic pseudoaneurysms.   
2.4. Technique of UGTI 
Our unit has adapted the original technique for UGTI described by Kang et al  for the 





by a vascular surgeon (or senior surgical fellow), together with a specialist vascular 
ultrasonographer. The patient is placed in the supine position. The ultrasonographer uses B-
mode and colour flow imaging to define the pseudoaneurysm. As a baseline, pre-procedure 
imaging of adjacent major vessels (e.g. common femoral artery and vein) is performed. 500 
IU of lyophilised human thrombin is dissolved in 1ml calcium chloride solution. This is 
drawn into a 2ml syringe and a 22 gauge spinal needle is attached. 
A safe angle of approach to the aneurysm sac is confirmed by the ultrasonographer and 
vascular surgeon. The area of skin puncture is prepared with chlorhexidine solution. The 
ultrasonographer provides a constant good view of the pseudoaneurysm using B-mode 
imaging while the needle is advanced slowly into the pseudoaneurysm cavity. The needle 
tip is positioned away from the neck of the pseudoaneurysm, but within a flowing 
component of the sac. Appropriate positioning within the sac is confirmed by the 
ultrasonographer using multiple views. Once the ultrasonographer and vascular surgeon 
are satisfied with the needle position, thrombin injection is performed. On occasions, the 
needle tip may be difficult to identify on ultrasound and a 20 gauge spinal needle is used to 
improve visualisation.  
Thrombin injection is then performed slowly under constant colour flow imaging to observe 
thrombosis of the aneurysm sac. When colour flow within the cavity stops completely, 
injection is ceased. It is uncommon for us to require more than 0.25ml of thrombin solution 
to achieve thrombosis, even for relatively large pseudoaneurysms. Another way of ensuring 
controlled injection of thrombin is to administer small (e.g. 0.125ml) aliquots of solution at a 
time whilst assessing colour flow within the aneurysm sac. 
All patients are followed up at one week with repeat duplex ultrasound. Further injections 
may be undertaken at this stage if deemed appropriate. We advise caution and 
consideration of alternative treatment if more than two injections are required. 
2.5. Infected femoral pseudoaneurysms 
Infected femoral pseudoaneurysms are more commonly seen in the intravenous drug using 
(IVDU) population, arising from repeated non-sterile needle groin punctures as part of the 
pursuit of easy peripheral venous access. However, it may also complicate iatrogenic 
pseudoaneurysms. Clinical presentation mirrors that for non-infected femoral 
pseudoaneurysms, with the added serious complication of infection. The ‘aneurysmal 
abscess’ carries with it a significant risk of sepsis, rupture, limb loss and death.[15] 
Diagnosis can be made by DUS, but direct DUS imaging can be challenging due to 
inflammation and even gas. CTA avoids these problems, and can give an appreciation of the 
extent of inflammation/infection.  
Primary repair is not recommended as appropriate surgical management by some authors 
because the ongoing infection and destruction of the arterial wall usually results in 
secondary haemorrhage and infection.[15] Ligation and excision of the infected artery and 
pseudoaneurysm, with aggressive debridement of surrounding infected tissue is the 
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preferred approach. There is debate among vascular surgeons regarding whether a bypass 
procedure is required during the same operation.[15]  
 
Figure 1. Panel A- DUS of femoral pseudoaneurysm demonstrating “to and fro” flow (yellow arrow) 
between the native artery and the pseudoaneurysm via the neck. There is colour signal in the 
pseudoaneurysm (white arrow) representing active blood flow.  Panel B: Thrombosed pseudoaneurysm 
following UGTI. The pseudoanerusym sac now contains newly formed thrombus (blue arrow). Note the 
residual blood flow within the pseudoaneurysm neck after thrombosis of the pseudoaneurysm sac. 
In our experience, ligation and excision of the infected artery and pseudoaneurysm, with 
aggressive debridement of surrounding infected tissue is well tolerated overall. This also 
avoids extended procedure times and potential complications associated with infection of 
bypass grafts. A recent review publication by Georgiadis et al showed an early occurrence of 
rest pain in 10.8% of patients and early risk of amputation in 5.7% of patients. Triple ligation 
(for pseudoaneurysms occurring at the common femoral bifurcation) likely results in worse 
outcomes for patients than single ligation.[15] In these patients, we advocate close 
monitoring of the affected limb in the immediate post-operative period and consideration 
for immediate extra-anatomical bypass if signs of limb-threatening ischemia develop. 
2.6. Other peripheral iatrogenic pseudoaneurysms 
In addition to femoral pseudoaneurysms, the most common sites for iatrogenic 





iatrogenic pseudoaneurysms, most peripheral iatrogenic pseudoaneurysms occur following 
catheterisation of the affected artery.  Clinical features will vary depending on the location 
and size of the pseudoaneurysm. Symptoms and signs will relate to the pseudoaneurysm 
itself and its effects on neighbouring structures. For example, brachial pseudoaneurysms 
often cause pain and swelling in the cubital fossa, along with a palpable mass. The mass 
may be pulsatile with a thrill or bruit. Compression of the adjacent brachial veins or median 
nerve can occur, as well as ischaemic compromise of the overlying skin. Arm swelling, deep 
vein thrombosis, compressive neuropathy, skin necrosis and rupture are also potential 
complications. Similarly, DUS is the modality of choice for diagnosis of other peripheral 
pseudoaneurysms, particularly in centres with a dedicated vascular ultrasound laboratory. 
CTA is best relied on in centres without ready access to vascular ultrasound services, in 
cases where duplex ultrasound findings are equivocal or the anatomy is not well defined.  
The options available for management of peripheral pseudoaneurysms are the same as for 
femoral pseudoaneurysms. Given easy percutaneous access to the peripheries, UGTI should 
be the treatment of choice for all suitable iatrogenic peripheral pseudoaneurysms. Published 
series have reported successful outcomes of UGTI with pseudoaneurysms involving the 
femoral, popliteal, tibial, axillary, brachial and radial arteries.[16] Radial artery iatrogenic 
pseudoaneurysms following arterial line insertion in critical care settings can be better 
treated with radial artery ligation if there is clinically good perfusion via the ipsilateral ulnar 
artery.  
Carotid artery pseudoaneurysms are a rare subset of pseudoaneurysms. Carotid aneurysms 
make up less than 1% of all carotid pathologies, and of these, roughly 1 in 3 are 
pseudoaneurysms.[13] In modern practice, the more common causes include inadvertent 
catherisation during attempted internal jugular vein central line placement, trauma (blunt or 
penetrating), and pseudoaneurysm formation in the anastomotic suture line following 
carotid endarterectomy. Local infection (e.g. TB, syphilis) causing pseudoaneurysm 
formation is rarely seen these days. 
A pulsatile neck mass is the most common clinical presentation, followed by neurological 
symptoms such as TIA, stroke and Horner’s syndrome.[13] Diagnosis can again be made by 
duplex ultrasound, however, with the possibility of endovascular intervention, CTA is best 
to define aortic arch anatomy and suitability for endovascular repair. The potential severe 
sequelae of carotid pseudoaneurysms mandates surgical intervention. Given small numbers, 
only case series data is available for different types of carotid aneurysm repair, with only a 
small subset of these comprising pseudoaneurysms. Open surgical intervention includes 
resection and patch angioplasty, resection and interposition grafting, and ligation.[13] The 
latter should be considered a last resort. Surgical reconstruction of all types of carotid 
aneurysm is associated with a combined stroke and mortality rate of about 10%.[17] 
Endovascular interventions include covered stent grafts, bare stenting with trans-stent 
coiling, autogenous vein covered stents, and endovascular balloon occlusions.[13] Outcome 
data is limited to case series, but the data is promising. In a large single-centre series 
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spanning 20 years, Zhou et al report that endovascular intervention is an effective 
alternative to open surgery, particularly for patients with high surgical risk or distally 
located aneurysms that preclude a safe surgical approach.[13] 
2.7. Visceral iatrogenic pseudoaneurysms  
Iatrogenic pseudoaneurysms arising from the thoraco-abdominal aorta and other visceral 
branches have all been reported. These are typically the complications of prior surgery 
(vascular or non-vascular) or endovascular intervention of arterial or venous 
pathologies.[18-21] Patients with visceral iatrogenic pseudoaneurysms may remain 
chronically asymptomatic with detection only after investigation for other complaints. 
Alternatively, presentation may be with local compressive symptoms, or even rupture. 
Endovascular treatment in the form of direct thrombin injection [22], coiling [23], occlusion 
devices [24], and endograft stenting [25,26] have all been described and often considered be 
first line option of treatment in most cases [27,28]. Open surgical repair of visceral iatrogenic 
pseudoaneurysms can be challenging, especially when in a previously exposed surgical field. 
Although there has been increasing utilization of endovascular techniques for the treatment of 
visceral iatrogenic pseudoaneurysms, there remains a clear role for OSR in selected situations, 
such as when local mass effect of pseudoaneurysms requires concurrent treatment.[27]  
3. Conclusion 
The incidence of iatrogenic pseudoaneurysms is increasing as a result of progressive uptake 
of percutaneous arterial interventions for cardiovascular disease and the increased use of 
combination antiplatelet therapy. Femoral iatrogenic pseudoaneurysms represent the most 
common form of this pathology, but the incidence of other peripheral / visceral 
pseudoaneurysms is also likely to increase in the future. In experienced hands, thrombin 
injection under DUS guidance can offer prompt resolution of the pathology. However, no 
large randomized trials to date have definitively addressed the efficacy of this treatment 
technique. Physicians should be aware of the potential for pseudoaneurysm formation 
following percutaneous arterial interventions, and be familiar with the clinical findings and 
potential treatment options. 
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